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7Summary
The hematopoietic-specific Rho-family GTP exchange factor (GEF) Vav-1 is a regulator of
lymphocyte antigen receptor signaling and mediates normal maturation and activation of B
and T cells. Recent findings suggest that Vav-1 also forms part of signaling pathways
required for natural and antibody dependent cellular cytotoxicity (ADCC) of human NK cells.
In this study, I show that Vav-1 is also expressed in murine NK cells. Vav-1-/- mice had
normal numbers of splenic NK cells, and these displayed a similar expression profile of NK
cell receptors as cells from wild type mice. Unexpectedly, IL-2-activated Vav-1-/- NK cells
retained normal ADCC. Fc-receptor mediated activation of ERK, JNK, and p38 was also
normal. In contrast, Vav-1-/- NK cells exhibited reduced natural cytotoxicity against EL4,
C4.4.25, RMA and RMA/S. Together, these results demonstrate that Vav-1 is dispensable for
mainstream NK cell development, but is required for NK cell natural cytotoxicity. Vav-2, a
protein homologous to Vav-1 has also been implicated in NK cell functions. However, NK
cells from Vav-2-/- mice have normal cytotoxic activities and NK cells that lack both Vav-1 and
Vav-2 exhibit similar defect as Vav-1-/- cells. Thus Vav-2 has no apparent function in the
development and the activation of NK cells. Although NK cell development is normal in Vav-
1-/- mice, their numbers of NKT cells were dramatically diminished. Furthermore, NKT cells
from Vav-1 mutant mice failed to produce IL-4 and IFNg following in vivo CD3 stimulation. A
similar loss of NKT cells was observed in Vav-1-/-Vav-2-/- mice, but not in Vav-2-/- mice,
8suggesting that only Vav-1, and not Vav-2, is an essential regulator of NKT cell development
and NK cell cytotoxicity.
Similar to Vav-1, Lsc is a Rho GEF that is expressed specifically in the hematopoietic
system. It contains a regulator of G-protein signaling (RGS) domain which negatively
regulates the Ga 12 and Ga 13 subunits of G-protein coupled receptors (GPCRs). This study
shows that NK and NKT cell development are normal in Lsc-/- mice. However, NK cells from
mutant mice display enhanced cytotoxic responses towards a panel of tumor cells. These
data implicate for the first time a RGS-containing Rho GEF in cytotoxic responses and
suggest that Lsc down-modulate NK cell activation.
9Zusammenfassung
Vav-1 ist ein spezifisch in hämatopoetischen Zellen exprimierter Guanin-Nukleotid-
Exchange-Faktor (GEF) für Rho-GTPasen, der die Antigenrezeptor-vermittelte
Signaltransduktion in Lymphocyten reguliert und essentiell für der Reifung und Aktivierung
von B- und T-Zellen ist. Untersuchungen an menschlichen Zellen lassen vermuten, dass
Vav1 auch für Antikörper-unabhängige, natürliche Zytotoxizität und die Antikörper-abhängige
zellvermittelte Zytoxizität (ADCC) von „Natürlichen-Killerzellen“ (NK-Zellen) wichtig ist. In der
vorliegenden Arbeit zeige ich, dass Vav-1 auch in murinen NK-Zellen exprimiert ist. Analysen
von Vav-1-/--Mäuse zeigen eine normale Anzahl von NK-Zellen, die wiederum ein ähnliches
Expressionsprofil von typischen NK-Zell-Rezeptoren im Vergleich zu wildtypischen Mäusen
aufweisen. Die ADCC von Vav-1-/- NK-Zellen ist unverändert, wie auch die Fc-Rezeptor
vermittelte Aktivierung von ERK, JNK und p38. Im Gegensatz dazu zeigen Vav-1-/- NK-Zellen
eine reduzierte natürliche Cytotoxizität gegenüber EL4-, C4.4.25-, RMA- und RMA/S-
Zielzellen. Vav-1 ist daher nicht für die Entwicklung, sondern für den Aufbau der natürlichen
Cytotoxizität von NK-Zellen von Bedeutung. Für Vav-2 wurde ebenfalls eine Rolle in NK-
Zellfunktionen wahrscheinlich gemacht. Dennoch zeigen Vav-2-/- Mäuse ein normales
zytotoxisches Verhalten. NK-Zellen von Vav-1/Vav-2-doppeldefizienten Tieren weisen
ähnliche Defekte wie NK-Zellen von Vav-1-defizienten Tieren. Somit besitzt Vav-2 keine
entscheidende Funktion für die Entwicklung und Aktivierung von NK-Zellen. Im Gegensatz zu
NK-Zellen ist die Anzahl der NKT-Zellen in Vav-1-/- Mäusen drastisch reduziert. Außerdem
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sind NKT-Zellen Vav-1-defizienter Mäuse nicht in der Lage IL-4 und INFg  nach CD3-
Stimulierung in vivo zu produzieren. Ein ähnlicher Verlust der NKT-Zell-Population wurde in
Vav-1-/-- Vav-2-/--Mäusen beobachtet, nicht aber in Vav-2-/- Mäusen. Daher scheint nur Vav-1,
nicht aber Vav-2, ein essentieller Regulator sowohl der NKT-Zell-Entwicklung als auch der
NK-Zell-Cytotoxizität zu sein. Ein weiterer Rho-GEF, Lsc, ist ebenfalls spezifisch im
hämatopoetischen System exprimiert. Lsc besitzt auch eine negativ-regulatorische RGS-
Domäne (regulator of G-protein signaling) für die Ga 12- und Ga 13-Untereinheiten von G-
Protein-gekoppelten Rezeptoren. NK- und NKT-Zellen von Lsc-defizienten Mäusen
entwickeln sich normal, weisen aber eine erhöhte Cytotoxizität gegenüber einer Reihe von
Tumor-Zellen auf. Diese Daten zeigen zum ersten mal die Beteiligung eines RGS-Rho-GEF
an zytotoxischen Reaktionen und deuten auf eine negative Modulation der NK-Zell-
Aktivierung durch Lsc hin.
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1. Introduction
1.1 NKT cells
Natural killer (NK) T cells are important for tumor rejection, prevention of autoimmunity,
protection against bacterial infections, and modulating T cells cytokine profiles. Mouse NKT
cells express typical NK markers such as NK1.1, members of the Ly49 family, and IL-2Rb ,
demonstrating developmental and/or activation characteristics reminiscent of NK cells
(Godfrey et al., 2000). Many NKT cells are positively selected by CD1, a b 2-microglobulin
(b 2m) associated MHC class I like molecule (Porcelli and Modlin, 1999). The CD1-restricted
NKT cells are localized mostly in the thymus and the liver, but also present in the bone
marrow and the spleen in lower numbers. These NKT cells express a TCR repertoire with a
biased Va  chain usage: in humans mainly Va 24J a Q pairing with Vb 11, and in mice mainly
Va 14J a 281 paired with Vb 8.2,Vb 7 and Vb 2 (Godfrey et al., 2000).  CD1d restricted NKT
cells are predominately CD4+ or CD4-CD8-(DN). CD1-independent NKT cells, on the
contrary, are either CD8+ or DN.  They have a diverse TCR repertoire, and are mostly found
in the spleen and the bone marrow. Whether there exist any functional difference between
CD4+ and CD8+ NKT cells is not known (Eberl et al., 1999b; Emoto et al., 2000; Godfrey et
al., 2000; Hammond et al., 1999; Hammond et al., 2001).
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Gene-ablation studies revealed many molecules are necessary for NKT cells development.
These mutants exhibit profound NKT cell deficiencies (Table 1.1).  Interestingly one naturally
occurring mice strain, SJL, also exhibit a selective reduction of NKT cells (Yoshimoto et al.,
1999). The cause of this defect is still unknown. Although the ontology of NKT cells is not
well characterized, mice deficient in Lck, pre-TCRa , D45, CD3z  and ZAP-70 exhibit
developmental defect in both T cell and NKT cell compartments, highlighting possible
common signaling pathways in maturation of these two lineages. However, Fyn-/-, LTa -/- and
LTb -/- mice showed a normal maturation of conventional T cells but a mark reduction in the
number of NKT cells. These observations indicate that the ontology of conventional T cells
and NKT cells have similar but not identical signaling requirements.
Although NKT cells have been implicated in various immune responses, their precise roles
and their mechanisms of activation remain largely unknown. In vitro, CD3 ligation of thymic
and splenic NK T cells leads to the release of IL-4 (Hammond et al., 1999).  Thymic NKT
cells but not splenic NKT cells can also secrete moderate amount of IFNg  in response to CD3
stimulation. In vivo, injection of CD3 lead to a prompt and robust release of IL-4 by splenic
NKT cells (Yoshimoto and Paul, 1994). This response is largely abrogated in mice that are
deficient in NKT cells (Chen et al., 1997; Cui et al., 1999; Gadue et al., 1999; Mendiratta et
al., 1997; Yoshimoto et al., 1999). Since NKT cells are capable of releasing large amount of
IL-4, it was speculated that their activation might polarize a Th2 response. However,
activation of NKT cells can also trigger NK cells to release large amount of IFNg
15
Table 1.1.  Gene-ablation mutations that lead to aberration of NK T cell ontology
Mice  mutation NKT cells Reference
b 2M
CD1d
pre-TCRa 
CD3z 
ZAP-70
CD45
Lck
Fyn
Vav-1
J a 281
TCF-1
IRF-1
LTa
LTb 
IL-7Ra
IL-2Rb /IL-15Rb
g c
IL-15Ra
IL-15
SJL (naturally
occuring stain)
Severely reduced
Severely reduced
Severely reduced
Severely reduced
Severely reduced
Reduced
Reduced
Reduced
Reduced
Severely reduced
Reduced
Reduced
Severely reduced
Severely reduced
Reduced
Reduced
Severely reduced
Reduced
Reduced
Reduced
(Bendelac et al., 1992; Coles and Raulet, 1994)
(Chen et al., 1997; Mendiratta et al., 1997; Smiley et al., 1997)
(Eberl et al., 1999a)
(Arase et al., 1995)
(Iwabuchi et al., 2001)
(Martin et al., 2001)
(Eberl et al., 1999c; Gadue et al., 1999)
(Eberl et al., 1999c; Gadue et al., 1999)
(Chan et al., 2001; Colucci et al., 2001)
(Cui et al., 1997)
(Ohteki et al., 1996)
(Ohteki et al., 1998)
(Elewaut et al., 2000)
(Elewaut et al., 2000)
(Boesteanu et al., 1997)
(Ohteki et al., 1997)
(Boesteanu et al., 1997)
(Lodolce et al., 1998)
(Kennedy et al., 2000)
(Yoshimoto et al., 1999)
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(Carnaud et al., 1999). Whether NKT cell activation polarize a Th2 response in vivo remain
unresolved.
Natural occurring antigens that could trigger NKT cell activation remains obscure. CD1d
independent NKT cells have a diverse TCR expression and it was suggested that they bind
to conventional MHC-peptide complexes (Eberl et al., 1999b; Hammond et al., 1999). While
CD1d dependent NKT cells probably recognize CD1d in conjunction with hydrophobic
ligands (Benlagha et al., 2000; Burdin and Kronenberg, 1999).  Until now, no natural ligand
for CD1d restricted NKT cells has been identified. a -galactosylceramide (a GalCer), a
glycosphingolipid derived from marine sponge Agelas mauritanius can bind to CD1d and
strongly stimulate NKT cells (Burdin et al., 1998; Kawano et al., 1997; Yamaguchi et al.,
1996). Exposure to a GalCer to NKT cells leads to massive production of both IFNg  and IL-4,
NK cell proliferation and cytotoxic responses (Carnaud et al., 1999; Eberl and MacDonald,
2000). In vivo, a GalCer treatment lead to anti-tumor immunity (Kawano et al., 1998;
Nakagawa et al., 1998), protection against murine malaria (Gonzalez-Aseguinolaza et al.,
2000) and prevention of type 1 diabetes in mice (Hong et al., 2001; Sharif et al., 2001).
Recent evidence suggested NKT cells also participate an immunosuppressive function.
Terabe et al. (2000) showed that a subset of CD4+ NKT cells can act as suppressors of CTL
mediated anti-tumor immunity. Furthermore, Moodycliffe et al. (2000) showed CD4+DX5+
cells plays a critical role in suppressing delayed type hypersensitivity (DTH). It is therefore
possible that different populations of NKT cells may exhibit unique cytokine profiles, allowing
them to execute different functions in vivo.
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1.2 NK cells
Natural killer (NK) cells are subset of lymphocytes that can contribute protective responses
against a variety of infections and tumors (Biron et al., 1999). They are bone marrow derived
and share a common progenitor with T cells. This is demonstrated by a subset of CD34+
human thymic precursors capable of differentiating into NK and T cells in fetal thymic organ
cultures (Sanchez et al., 1994). In both mice and human, NK cells comprise up to 5-15% of
peripheral blood lymphocytes and are found in the spleen, bone marrow, liver, lymph nodes
and lungs (Trinchieri, 1989). Unlike T and B cells, NK cells do not have antigen specific
receptors, instead they express a plethora of surface molecules that could discriminate
abnormal cells from healthy ones. These receptors deliver either stimulatory or inhibitory
signals, and it is the net balance of these signals that ultimately lead to promotion or
suppression of NK activation (Figure 1.1 and Table 1.2).
1.2.1 Inhibitory receptors of NK cell activation
Ly49 protein family
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NK Cell
Target Cell
NK Cell
Inhibitiors Activators
NK Cell
Target Cell
NK Cell
Ignore Target Kill Target
Inhibitiors Activators
Figure 1.1 A. NK cell acitivation in mediated by signal integration of stimulatory and inhibitory 
receptors on the cell surface. Normal target cells express more inhibitors leading to tolerance. 
Tumor and viral infected targets down-regulate inhibitors and up-regulation of activators, thereby 
rendering them sensitive to NK cell lysis. B.  Major NK cell stimulatory and inhibitory receptors.
Inhibitory
Ly-49
Qa-1
CD94-
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SHP-1
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M
Y
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DAP10
NKG2D
IT
A
M
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A
M
IT
A
M
IT
A
M
IT
A
M
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A
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NKp30
CD3
NKp46
IT
A
M
IT
A
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PI3K
AKT
Activation
CD94-
NKG2C
IT
A
M
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A
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Ly-49
DAP12
Syk kinase
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A
M
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A
M
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RAE-1
H-60 HA HA?
A
B
Interaction of charge residues in the transmembrane of receptors.
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Table 1.2. Activators and Inhibitors on NK cells
NK cell Receptors Species Ligands Signaling Components
Activators
NKR-P1C (CD161)
Ly49D
Ly49H
CD94/NKG2C
KIR2DS
NKG2D
2B4 (CD244)
NKp46
NKp30
NKp44
Lag-3
Inhibitors
Ly49A
Ly49C
Ly49G2
Ly49I
Ly49F
CD94/NKG2A/B
M
M
M
M, H
H
M, H
M, H
M, H
M
M
M, H
M
M
M
M
M
M, H
unknown
H-2Dd
unknown
Qa-1b (M), HLA-E (H)
HLA-C
RAE-1 (M), H-60 (M), MICA/B (H)
CD48
Viral hemaglutinin
unknown
Viral hemaglutinin
MHC class II
H-2Db,d,k,p, H-2s
H-2Kb,d,H-2Db,d,k,H-2s
H-2Dd,r, H-2k
H-2Kd,H-2b,d,k,s
H-2d
Qa-1b (M), HLA-E (H)
Fce R g I
DAP12,Syk, ZAP70
DAP12
DAP12
DAP12
DAP10, PI3K
SAP, LAT
Fce R g I, CD3z , PI3K, AKT
CD3z , PI3K, AKT
DAP12
?
SHP-1
SHP-1
SHP-1
SHP-1
SHP-1
SHP-1
M, mouse. H, human.
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NK cells express a variety of different inhibitory receptors. In humans, inhibition is mediated
by killer immunologlobin-related receptors (KIR), a type I transmembrane protein belonging
to the Ig superfamily that binds specific HLA class I molecules (Long, 1999). In mice,
inhibition is mediated by Ly49 family members, which are type II transmembrane proteins of
the c-type lectin superfamily (Long, 1999). Despite the difference in membrane topology,
both of these inhibitors transduce their signals via a conserved mechanism. They contain
immunoreceptor tyrosine-base inhibitory motifs (ITIMs), which are phosphorylated upon
receptor engagement. This leads to the recruitment and activation SHP-1, a phosphatase
that dephosphorylates proteins in the activation signaling cascade of NK cells, thus inhibiting
cell activation (Long, 1999).
Ly49 family comproses of at least 21 members.  Among these, 13 are likely to be inhibitors,
based on the presence of an ITIM in their cytoplasmic domain. They include Ly49 A, B, C, E,
F, G, I, J, O, Q, S, T and V.  The rest of the family members are activators (Kane et al.,
2001)(see below).  All Ly49 proteins bind to class I MHC, but each one is distinct in their
allelic specificities. For example, Ly49A recognize H-2Db,d,k,p and H-2s, while Ly49G2
recognize H-2Dd,r and H-2k (Hanke et al., 1999; Takei et al., 1997). The expression of Ly49
members is mouse strain specific. For example, Ly49A and Ly49B are express on C57BL/6,
BALB/c, NOD, but not 129/J, 129/Svj, NZB, and CBA/J, while Ly49C is expressed in
C57BL/6, BALB/c and 129/Svj but not other strains (Kane et al., 2001). It is partly due to the
difference in Ly49 expression that NK cells of various mouse strains display unique target
specificity and susceptibility.
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CD94/NKG2
NKG2 proteins belong to another lectin-like receptor family known to act as inhibitors in NK
cells.  These include NKG2A/B, NKG2C, and NKG2E (NKG2A and B represent alternative
splice variants). In contrast to Ly49 proteins, which bind to conventional MHC class I, these
receptors bind to non-classical MHC molecules such as HLA-E in humans and Qa-1 in mice
(Braud et al., 1998; Vance et al., 1999; Vance et al., 1998).  Both HLA-E and Qa-1 present
MHC class I-derived leader peptides, which are peptides cleaved by signal peptidases in the
ER membrane during protein synthesis (Braud et al., 1998; Vance et al., 1998).  All NKG2
proteins (except NKG2D) heterodimerize with CD94. CD94 contains a very short cytoplasmic
domain with no identifiable motifs (Lanier et al., 1998a). In contrast, NKG2A/B posses
cytoplasmic ITIMs which can recruit SHP-1 upon receptor engagement (Lanier et al., 1998a).
NKG2C and NKG2E are structurally different from NKG2A/B and act as NK stimulatory
receptors (see below).
1.2.2 Stimulatory receptors of NK cell activation
Similar to inhibitory receptors, stimulatory NK cells receptors bind to MHC class I molecules.
They contain in their transmembrane domains charged residues that could associate with
adapter proteins. These adapters include DAP10 and DAP12. The latter contains
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immunoreceptor tyrosine-based activation motifs (ITAMs) in its cytoplasmic tail, which allow it
to associate with Syk family kinases (Lanier et al., 1998b; Olcese et al., 1997). DAP10, on
the other hand, contains in its cytoplasmic tail a YxxM motif which upon tyrosine
phosphorylation can recruit the p85 subunit of PI3-kinase (PI3K) (Wu et al., 1999). Pathways
downstream of DAP12 and DAP10 are not known.
NKp30, NKp44 and NKp46
A group of NK stimulatory receptors belonging to the Ig- superfamily were identified in human
(Moretta et al., 2001). These include NKp46, NKp44, and NKp30. NKp46 and NKp30 are
expressed in both resting and activated NK cells. They contain in their transmembrane
domains positive charged arginines which interact with aspartic acid residues in the
transmembrane domains of CD3z  and Fce RI g (Pende et al., 1999; Sivori et al., 1997). Both
NKp46 and NKp30 can activate PI3K and AKT (Spaggiari et al., 2001). To date, only the
NKp46 mouse homologue has been identified as MAR-1 (Biassoni et al., 1999). Unlike
NKp46 and NKp30, NKp44 is not expressed on resting human NK cells but is upregulated
after IL-2 stimulation. Therefore, it might participate in LAK cell mediated cytotoxicity (Vitale
et al., 1998). NKp44 is also found in a subset of gd  T cells (Vitale et al., 1998) and it
associates with KARAP/DAP12 (Cantoni et al., 1999). Antibodies directed against NKp46,
NKp44 and NKp30 can trigger intracellular Ca2+ mobilization and lysis of tumor targets in an
antibody redirected cytotoxic assay. Conversely cytotoxicity against tumor targets can be
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blocked by including neutralize antibodies against these molecules in the assay, indicating
that NKp30, NKp44 and NKp46 are key receptors for NK cell mediated tumor lysis (Moretta
et al., 2001).
Ly49D and Ly49H
In contrast to the negative regulatory receptors of the Ly49 family, ligation of Ly49D and
Ly49H stimulate NK cytotoxicity (Mason et al., 1996; Smith et al., 2000). These activating
receptors do not contain cytoplasmic ITIMs, but instead they have transmembrane basic
residue enabling them to associate with adapter DAP12, an ITAM containing adapter (Smith
et al., 1998). DAP12 is indispensable for Ly49D and Ly49H expression as indicated by a
complete loss of these receptors on the surface of DAP12-/- NK cells (Bakker et al., 2000;
Tomasello et al., 2000). The ligand for Ly49D was identified as H-2-Dd (Nakamura et al.,
1999) whereas the ligand for Ly49H is not known. Ly49D not only activates cytotoxicity
against allogenic targets, it is also involved in the killing of xenogenic targets such as CHO
cells (Idris et al., 1999). The importance of DAP12 and Ly49D in this process is further
supported by the analysis of DAP12-/- NK cells, which showed compromised capacity in
killing CHO targets (Bakker et al., 2000; Tomasello et al., 2000). Ly49H is present in
C57BL/6 mice but absent in DBA/2 mice. The absence of Ly49H on the surface of NK cells
render DBA/2 susceptible to mouse cytomegalovirus (MCMV) infection. Conversely, the
depletion of Ly49H+ NK cells from C57BL/6 mice, which are MCMV-resistant, leads to a
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MCMV-susceptible phenotype. These data demonstrated Ly49H is the essential in
controlling MCMV infection in mice (Brown et al., 2001; Daniels et al., 2001; Lee et al., 2001).
CD94/NKG2C and NKG2E
NKG2 family members heterodimerize with CD94 and bind to the non-classical MHC class I
molecules HLA-E and Qa-1. In contrast to NKG2A/B, NKG2C and NKG2E are activating
receptors. They posses charged residues in their transmembrane domains that enable them
to associate with adapter protein KARAP/DAP12 (Lanier et al., 1998a). Recruitment of
DAP12 to the activated receptors leads to further activation of Syk family kinases (Lanier et
al., 1998b; Olcese et al., 1997).
NKG2D
Another activator expressed on NK cells is NKG2D, a type II c-type lectin molecule. Unlike
NKG2A, NKG2C, or NKG2E, NKG2D does not heterodimerized with CD94. Instead it is
expressed as a homodimer on NK cells, ab  and gd  T cells and LPS stimulated macrophages
(Bauer et al., 1999; Diefenbach et al., 2000). NKG2D has two charged residues in its
transmembrane domain which associate DAP10/KAP10, which can in turn recruit PI3K
(Chang et al., 1999; Wu et al., 1999). NKG2D bind to MHC class I-like molecules H60 and
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Rae1 in mouse cells (Cerwenka et al., 2000; Diefenbach et al., 2000) and MICA/B and
ULBPs on human cells (Bauer et al., 1999; Cosman et al., 2001). Interestingly, a HCMV
(human cytomegalovirus)-encoded glycoprotein, UL16, was recently identified to be a ligand
of MICB and ULBPs, thus highlighting a possible mechanism use by viruses to mask NK cell
activation signals (Cosman et al., 2001).
NKR-P1
Four highly related genes - nkr-p1a, nkr-p1b, nk-p1c and nk-p1d - have been identified in
rodents and they encode receptors of the c-type lectin family. NKR-P1A and NKR-P1C are
stimulatory isoforms and are widely express on NK cells, whereas NKR-P1B and NKR-P1D
are inhibitory isoforms and exhibit limited expression in C57BL/6 mice (Carlyle et al., 1999;
Chambers et al., 1989; Giorda et al., 1990; Giorda and Trucco, 1991; Giorda et al., 1992;
Ryan et al., 2001; Yokoyama et al., 1991). NKP-P1B mediates inhibition through the
recruitment of SHP-1 to its cytoplasmic ITIM (Carlyle et al., 1999). The best characterized
member, NKP-P1C (also known as NK1.1) associates with Fce R g I in mediating its
downstream signaling (Arase et al., 1997). Rat NKP-P1C also has a CxCP motif in its
cytoplasmic domain that constitutively associates with p56lck (Campbell and Giorda, 1997).
Cross-linking of NKR-P1C activates NK cells (Arase et al., 1996; Karlhofer and Yokoyama,
1991; Ryan et al., 1991). The physiological ligands for NKR-P1 receptors remain unknown.
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2B4
2B4 (CD244) is expressed in NK cells, monocytes and a subset of CD8+ T cells (Garni-
Wagner et al., 1993; Valiante and Trinchieri, 1993). It binds to CD48, a broadly expressed
GPI-anchored molecule of unknown function (Brown et al., 1998; Kubin et al., 1999;
Latchman et al., 1998; Nakajima et al., 1999). Ligation of 2B4 leads to phosphorylation of the
tyrosine motif (TxYxxI/V) in the cytoplasmic tail, resulting in the recruitment of the adapter
SH2D1A/SAP (Coffey et al., 1998; Nichols et al., 1998; Sayos et al., 1998), SHP-1 (Parolini
et al., 2000) and SHP-2 (Tangye et al., 1999). It was recently reported that ligation of 2B4
could also lead to phosphorylation of the membrane adapter LAT and the association PLCg
and Grb2 with the receptor (Bottino et al., 2000).  Since 2B4 binds both SH2D1A/SAP and
SHP-2, it was suggested that 2B4 triggers NK cells activation by recruitment of
SH2D1A/SAP, which displaces SHP-2 from 2B4 (Parolini et al., 2000; Tangye et al., 1999).
Consistent with this hypothesis, mutation of SH2D1A/SAP in XLP (X-linked
lymphoproliferative disease) patients leads to an impairment of this adapter to associate with
2B4. As a result, 2B4 bound SHP-2 exclusively and functions as an inhibitory rather than a
stimulatory receptor (Parolini et al., 2000).
CD16
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IgG Ab-coated targets trigger natural killer cells cytotoxicity. This process, known as antibody
dependent cell mediated cytotoxicity (ADCC) is mediated by the low affinity receptor Fcg RIIIA
(or CD16), the only Fc receptor expressed in NK cells (Takai et al., 1994). Ligation of CD16
leads to Lck and Syk activation, increase in intracellular Ca2+ and PLCg -1 and PLC-g 2
activation (Azzoni et al., 1992; Ting et al., 1995; Ting et al., 1992). Triggering of CD16 also
leads to the phosphorlyaton of Vav-1 (Billadeau et al., 1998; Galandrini et al., 1999),
activation of p21Ras (Galandrini et al., 1996), PI3K (Bonnema et al., 1994; Kanakaraj et al.,
1994), NFATp and NFATc (Aramburu et al., 1995) and the activation of ERK, JNK and p38
pathways, leading to subsequent mobilization cytotoxic granules and the secretion of IFNg
and TNFa  (Chini et al., 2000; Milella et al., 1997; Trotta et al., 2000). Indeed both CD16-
mediated cytotoxic degranulation and IFNg and TNFa mRNA accumulation are in part
dependent on ERK and p38 activation (Chini et al., 2000; Milella et al., 1997; Trotta et al.,
2000).
1.2.3 Mechanisms of NK cell mediated tumor lysis
Mechanisms of NK cytotoxicity can be classified into secretory and non-secretory pathways.
The secretory pathway involved the mobilization and polarization of cytotoxic granules to the
sites of cell-cell contact upon NK cell activation. These granules are secreted, releasing
perforin which homopolymerizes to form pores on target cell membranes (Liu et al., 1995).
This leads to osmotic leakage of the target cells, thus allowing granzymes, another
components of cytotoxic granules, to enter and induce caspases-dependent and caspases-
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independent cell death (Smyth and Trapani, 1995). NK cells also secrete TNFa  in promoting
tumor cytotoxicity, as indicated by TNFa -/- NK cells which show reduced tumor lysis in vitro
and in vivo (Baxevanis et al., 2000). Activation of the non-secretory pathway is mainly due to
FasL on NK cells engaging with Fas on target cells (Kagi et al., 1994a; Lowin et al., 1994). In
addition, TRAIL was also implicated in the induction of target cell death by NK cells
(Kayagaki et al., 1999). Mechanism of NK cytotoxicity might be target specific, but the most
conserved mechanisms involve perforin and FasL (Kagi et al., 1994a; Kagi et al., 1994b;
Lowin et al., 1994). Incidentally, these are also used by CTL to lyse target cells (Kagi et al.,
1994a; Kagi et al., 1994b; Lowin et al., 1994).
1.3 Vav family of Rho GEFs
The Vav family belongs to the Dbl family of Rho guanine nucleoide exchange factors (GEFs).
Currently three members have been identified in mammals. These are Vav-1, Vav-2 and
Vav-3. Vav-1 is primary expressed in the hematopoietic system, whereas Vav-2 transcripts
are expressed in mouse liver, spleen, thymus, lung and testis (Schuebel et al., 1996).
Interestingly, Vav-2 protein is expressed in higher amount in B cells compared to T cells
(Tedford et al., 2001). Vav-3 show a broad patterns of expression. Two species of Vav-3
mRNA, 3.4 kb and 5.4 kb, are present in all tissues except the ovaries and the skeletal
muscles. Placenta, kidney, pancreas, and colon express highest level of the 3.4 kb
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transcripts, while spleen and peripheral blood lymphocytes express the highest level of the
5.4 kb species (Movilla and Bustelo, 1999; Zeng et al., 2000).
All Vav proteins have the same order of protein domains in their primary structure (Figure
1.2). These include a calponin homology (CH) domain; PH (pleckstrin homology) domain;
one Src homology (SH) 2 domain and two SH3 domains, for mediating protein-protein
interactions; and a Dbl homology (DH) domain, which catalyzes guanine nucleotide
exchange for Rho-family GTPases (Bustelo, 1996; Cantrell, 1998; Fischer et al., 1998b).
Vav-1 was discovered by its ability to transform fibroblasts (Katzav et al., 1989). Expression
of N-terminal truncated mutant of Vav-1 and Vav-2 leads to high levels of transformation in
NIH3T3 cells (Abe et al., 2000; Liu and Burridge, 2000; Schuebel et al., 1996; Schuebel et
al., 1998). Whereas elimination of the CH domain is sufficient to activate transformation by
Vav-1 (Coppola et al., 1991), deletion of both CH and AD domain is required to activate the
oncogenic potential of Vav-2 (Schuebel et al., 1996). Contentious data exist in regard to
whether Vav-3 can also transform rodent fibroblasts. Movilla and Bustelo (1999) showed that
both full length (FL) and truncated Vav-3 (D 1-444, CH-AD-DH and D 1-184, CH-AD) fail to
transform NIH 3T3 fibroblasts (Movilla and Bustelo, 1999), while Zeng et al (2000) showed
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Figure 1.2 A. Primary structures of Vav-1, Vav-2 and 
Vav-3. These include a calponin homology (CH) domain; 
PH (pleckstrin homology) domain; one Src homology 
(SH) 2 domain and two SH3 domains, for mediating 
protein-protein interactions; and a Dbl homology (DH) 
domain, which catalyzes guanine nucleotide exchange 
for Rho-family GTPases. The SH3-SH2-containing 
adaptor domains of Vav-1 were shown to associate with 
many signaling intermediates such as SLP-76, Syk, ZAP-
70, BLNK, CD19, Grb2. Vav-1 GEF activity could be 
positively modified by Lck-induced tyrosine 
phosphorylation of Y174 and by the binding of PI(3,4)P2, 
and PI(3,4,5)P3 to its PH domain.
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Figure 1.2 B. A model of the function of Vav-1 in T cells.
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 that over-expression of Vav-3 (D 1-114, CH) can lead to foci formation in these cells (Zeng et
al., 2000). In summary, these data led to the speculation that the CH and the AD domains
are involved in negative regulation of Vav activity (see below).
Vav-1 GEF activity can be activated by Lck-mediated tyrosine phosphorylation of Y174 and
modulated by the binding of PI(3,4)P2  and PI(3,4,5)P3 to its PH domain (Crespo et al., 1997;
Han et al., 1997; Han et al., 1998). Tyrosine phosphorylation of Vav-1 relieves autoinhibition
by exposing its DH domain, leading to an enhanced GEF activity towards Rho GTPases
(Aghazadeh et al., 2000). A similar mechanism is expected but not shown in the regulation of
Vav-2 and Vav-3.
Vav-1 preferentially activates Rac1 and RhoA, although catalytic activities towards Cdc42
has also been noted (Crespo et al., 1997; Han et al., 1997). Upon phosphorylation or N-
terminal truncation, Vav-2 expressed in insect cells can catalyze GDP-GTP exchange of
RhoA, RhoB and RhoG but not Rac1 and Cdc42 (Schuebel et al., 1998). However, bacterial
expressed Vav-2 DH fragment exhibited strong GEF activity for Rac1, Cdc42 and RhoA (Abe
et al., 2000). It is not known which GTPase is specially activated by Vav-3. Baculovirus-
expressed N-terminal truncated Vav-3 (D 1-144) can promote GDP-GTP exchange of Rac1,
RhoA, RhoG but not Cdc42 (Movilla and Bustelo, 1999). Lck phosphorylated full length (FL)-
Vav-3 can also catalyze Rac1 and RhoA but not Cdc42 (Movilla and Bustelo, 1999). In sharp
contrast, Zeng et al. (2000) showed that over-expression of FL-Vav-3 in NHI3T3 can lead to
the activation of Rac1 and Cdc42 but not RhoA (Zeng et al., 2000). It is possible that both
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methodology and cell background might account for activation of different GTPase by Vav
family proteins. Interestingly these studies implicate Rac1 is a downstream target of Vav-3.
This notion is further supported by the observation that IgM-mediated Rac1 activation is
compromised in Vav-3-/- DT40 chicken B cells (Inabe et al., 2002). Taken together, Vav-1,
Vav-2 and Vav-3 can catalyse Rac1 activation.
Vav family proteins function not only as Rho GEF, but they also contain adapter SH3-SH2-
SH3 domains that could recruit other signaling intermediates. Vav-1 adapter domains were
reported to associate with SLP-76 (Onodera et al., 1996; Wu et al., 1996), Syk (Deckert et
al., 1996), ZAP-70 (Katzav et al., 1994) and Grb2 (Ramos-Morales et al., 1995; Ye and
Baltimore, 1994). Vav-2 and Vav-3, on the other hand, are less well characterized. It was
shown that both Vav-2 and Vav-3 undergo tyrosine phoshorylation upon ligation of EGFR
and PDGFR and can directly bind to these receptors (Moores et al., 2000; Pandey et al.,
2000).
1.3.1 Vav-1
Vav-1 is a crucial regulator of T cell activation. Over expression of Vav-1 in Jurkat cells
activates NF-AT transcriptional activity. Interestingly, this process seems to be independent
of Vav-1 GEF catalytic activity, since a DH-dead version of Vav-1 displayed a similar effect,
suggesting that other domains are involved in Vav-1 mediated NFAT activation (Kuhne et al.,
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2000). Over-expressing Vav-1 also leads to the CD69 upregulation, JNK activation,
membrane translocation of PKCq  and actin polymerization (Villalba et al., 2000).
Furthermore, Vav-1 and PKCq  synergistically activate IKKb  and NFk B transcriptional
activities (Dienz et al., 2000). These observations show that Vav-1 is an important regulator
of T cell activation. This notion is further supported by genetic evidence from the analysis of
knock-out mice. Gene ablation of vav-1 results in severe impairment of thymic maturation. In
these mice, thymocytes are impaired in the transition from the CD4-CD8- (double negative,
DN) stage to CD4+CD8+ (double positive, DP) stage, and from the DP to CD4+ or CD8+
(single positive, SP) stage. This results in a reduction of SP cells and mature T cells in the
periphery (Fischer et al., 1998a; Fischer et al., 1995; Turner et al., 1997; Zhang et al., 1995).
The defect in the transition from DP to SP could be explained by an aberrant thymic positive
selection (Kong et al., 1998; Turner et al., 1997) and negative selection in Vav-1-/- mice
(Kong et al., 1998). Mutant thymocytes are also more resistant to superantigen mediated
deletion (Turner et al., 1997). Vav-1-/- T cells from the periphery show a compromised
response to CD3-induced proliferation and IL-2 secretion (Costello et al., 1999; Fischer et al.,
1998a; Tarakhovsky et al., 1995; Zhang et al., 1995). They are also impaired in primary
responses to antigen i  vivo (Penninger et al., 1999). On a molecular level, the defects in the
differentiation and activation of mutant T cells can be in part explained by a failure of Vav-1-/-
T cells to elicit TCR clustering following ligation (Fischer et al., 1998a) (Holsinger et al.,
1998). Furthermore, there is marked reduction of CD3-induced production of IP3, intracellular
calcium release, ERK and NFk B activation in Vav-1-deficient thymocytes and peripheral T
cells (Costello et al., 1999; Fischer et al., 1998a; Fischer et al., 1995; Holsinger et al., 1998;
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Kong et al., 1998; Turner et al., 1997). Recently it was reported that introducing cbl-c null
mutation in Vav-1-/- background can rescue the activation of CD3-mediated Cdc42 activation,
TCR clustering, T cell proliferation and T cell cytotoxicity. It does not however restore CD3-
mediated Ca2+ mobilization and IL-2 production (Krawczyk et al., 2000). These observations
led to the hypothesis that two signaling pathways exist downstream of Vav-1: one mediates
intracellular Ca2+ mobilization leading to NFAT activation and the other regulates cytoskeletal
re-organization via Cdc42/WASP. Both pathways are necessary in T cell activation.
The Vav-1 null mutation does not only affect T cells, but also other cells of the hematopoietic
system. Vav-1-/- mice have normal numbers of conventional B cells, but a diminished amount
of CD5+ B1 cells in the peritoneum (Fischer et al., 1998a; Turner et al., 1997). Mutant B cells
are impaired in IgM-induced proliferation and they show a reduction in CD19-mediated Ca2+
flux, PI(4,5)P2 production and Ig- and CD19-mediated JNK activation (O'Rourke et al., 1998).
Furthermore, bone marrow derived mast cells (BMMC) from Vav-1-/- mice exhibits reduced
antigen mediated degranulation and IL-2 and IFNg  production. Fce R-mediated PLCg 1 and
PLC g 2 phosphorylation, IP3 and PIP3 production, Ca
2+ mobilization and AKT activation are
also markedly compromised in mutant BMMC (Manetz et al., 2001). Taken together, Vav-1 is
essential for development of T and B1 cells and the activation of T cells, B cells and mast
cells. On a molecular level, Vav-1 traffics signals derived from antigen receptors. Common to
these receptors is the presence of ITAMs that can recruit Src- and Syk family kinases. This
suggest that other ITAMs containing receptors may also lie up-stream of Vav-1 in other cell
types of the hematopoietic system.
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1.3.2 Vav-2
 In Jurkat cells, CD3 ligation leads to tyrosine phosphorylation of both Vav-1 and Vav-2
(Doody et al., 2000). However, Vav-2 differs from Vav-1 in that it does not potentiate TCR-
mediated NFAT and NFk B-dependent transcriptional activity (Doody et al., 2000; Moores et
al., 2000). In fact, over-expression of Vav-2 dramatically suppressed TCR-mediated NFAT
activation (Tartare-Deckert et al., 2001). Vav-1 but not Vav-2 enhances TCR-induced Ca2+
mobilization (Doody et al., 2000). In B cells, BCR and CD19 engagement lead to tyrosine
phosphorylation of Vav-2 (Doody et al., 2000). Furthermore, both Vav-1 and Vav-2 can
synergize with IgM in potentiating NFAT transcriptional activity (Doody et al., 2000). Over-
expression of either Vav-1 or Vav-2 in Bal-17 B cells also enhances IgM-mediated Ca2+
mobilization (Doody et al., 2000).
Vav-2 knockout mice have normal development of T and B cells, however, they display a
mild impairment of TD and TI antigen responses and BCR-induced calcium flux (Doody et
al., 2001; Tedford et al., 2001). Vav-1/Vav-2 double knock out mice show similar T cell
developmental defects as observed in Vav-1-/- mice, however, the numbers of peripheral T
cells is more severely reduced in Vav-1-/-Vav-2-/- mice compared to Vav-1-/- mice. This
suggests that Vav-2 has an unrecognized function in T cells. In contrast to Vav-1 and Vav-2
single knockout mice, Vav-1-/-Vav-2-/- mice have a severe impairment of splenic B cell
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development in the transition from IgMhiIgDlo to IgMloIgDhi stages. In addition, mature double
knockout mutant B cells are refractory to IgM-induced proliferation and they show a complete
abolishment of BCR-induced intracellular calcium mobilization (Doody et al., 2001; Tedford et
al., 2001). These data suggest that in T cells, TCR mediated Ca2+ flux is Vav-1 dependent,
whereas in splenic B cells, both Vav-1 and Vav-2 are necessary components of the
signalsome which regulates intracellular calcium release. A functional compensation of Vav-1
and Vav-2 during B cell development in the spleen alludes the possibility that Vav proteins
may also complement each other in other hematopoietic cell types such as NK cells.
1.3.3 Vav-3
In Jurkat T cells, ligation of CD3 can leads to tyrosine phosphorylaton of exogenous
expressed Vav-3. In constrast to Vav-1, Vav-3 fails to potentiate TCR-mediated NFAT-
dependent transcription, but it is able to enhance TCR-mediated NFk B-dependent
transcriptional activity (Moores et al., 2000). In chicken DT40 B cells, gene disruption of Vav-
3 leads to a reduction of IP3 and Ca
2+ flux in respond to BCR stimulation. Rac1 activation,
PI3K and AKT activities are also attenuated in the Vav-3-/- B cells following BCR ligation
(Inabe et al., 2002). The roles of Vav-3 in murine T and B- development and activation
remain to be identified.
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1.4 Vav-1, Vav-2 and NK cells
Vav family members are known to facilitate many NK cell functions. Vav-1 was implicated in
potentiating human NK cell cytotoxicity (Billadeau et al., 1998; Billadeau et al., 2000;
Galandrini et al., 1999) and b 1 integrin-mediated IL-8 secretion via the activation of the Rac-
PAK-MKK3-p38 pathway (Mainiero et al., 2000). In human NK cells, ectopic expression of
Vav-1 potentiates ADCC (Billadeau et al., 1998), while inhibition of Vav-1 expression with
anti-sense oligonucleotides markedly reduced Fcg R mediated cytotoxic activity (Galandrini et
al., 1999). Furthermore, ligation of CD16 (FcRg III) leads to rapid tyrosine phosphorylation of
Vav-1 (Billadeau et al., 1998; Galandrini et al., 1999; Xu and Chong, 1996), implicating Vav-1
as a downstream target. Enhancement of NK tumorcidal activities mediated by over-
expression of Vav-1 requires a functional DH and PH domain, but not the CH domain
(Billadeau et al., 2000).  Interestingly mutant carrying Y->F substitution of Y142, Y160, and
Y174 in the AD domain can lead to greater increase in ADCC compare to wild type Vav-1,
implicating these as negative regulatory residues. Taken together, Vav-1 is implicated in
CD16 signals in human NK cells.
NK cells exhibit spontaneous cytotoxicity toward selective tumors targets. Upon engagement
of target cells with NK cells, Vav-1 is rapidly phosphorylated (Billadeau et al., 1998;
Galandrini et al., 1999). Human NK cell cytotoxic activity against K562 cells is also
potentiated by the over-expression of Vav-1 (Billadeau et al., 1998), while reduction of Vav-1
expression by anti-sense oligonucleotides markedly reduces NK cytotoxic activity (Galandrini
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et al., 1999). The DH domain is essential for mediating these responses, while the PH and
the CH domains are not required.  Similar to the increase in ADCC, mutating Y142, Y160,
and Y174 to phenylalanine also leads to an enhancement of cytoxicity, highlighting again the
negative regulatory roles of these three tyrosine residues (Billadeau et al., 2000).
Vav-2 also has been described to participate in both NK natural cytotoxicity and ADCC since
FcR ligation leads to Vav-2 phosphorylation and ectopic expression of Vav-2 increases NK
natural cytotoxicity and ADCC. This process requires functional DH and SH2 domains of
Vav-2. The PH domain is also required for ADCC and natural cytotoxicity against selective
tumor targets (Billadeau et al., 2000). Together, these observations suggest both Vav-1 and
Vav-2 are involved in NK cell activation.
Several lines of evidence suggested that upstream modulators and downstream targets of
Vav-1 in T cells are also crucial signaling components in mediating NK cell activation. These
include LAT, PI3K and ERK. Vav-1 can be recruited to the adapter LAT following TCR
stimulation via the interactions of phosphorylated LAT with the SLP-76 SH2 domain and
phoshorylated SLP-76 binding to Vav-1 SH2 domain (Zhang et al., 1998). Coincidently, over-
expression of LAT in NK cells augments spontaneous cytotoxicity (Jevremovic et al., 1999).
Similar to LAT, PI3K is also a modulator of Vav-1 as indicated by the ability of its substrates
PI(3,4)P2, and PI(3,4,5)P3 to bind directly to Vav-1 PH domain and thereby enhance its GEF
activity (Han et al., 1998). PI3K also has a pivotal role in the regulation of NK cell activation
as the presence of PI3K inhibitors Ly294002 or wortmannin compromises NK cell-mediated
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tumor lysis (Jiang et al., 2000). ERK, another key component of T cells activation, is a
downstream target of Vav-1 in T cells derived from some mice strains (C57BL/6 and 129
mice but not CD1 mice) (my unpublished observation) (Costello et al., 1999; Fischer et al.,
1998a). Interesting ERK is also required for perforin and serine proteases release in NK cells
(Trotta et al., 1998; Wei et al., 1998). Together these observations suggest that Vav-1
dependent signaling pathways are involved in activation of both T cells and NK cells.
1.5 Lsc/p115 Rho GEF
Similar to Vav-1, Lsc/p115 Rho GEF is expressed primarily in cells of the hematopioetic
system (Girkontaite et al., 2001). Lsc was identified as a GEF specific for RhoA with
minimum catalytic activities towards Cdc42, Rac1 and Ras (Hart et al., 1996). Similar to
other GEFs, Lsc contains a tandem DH-PH domain for catalyzing activation of RhoA
GTPases (Hart et al., 1998). It also has a RGS domain that stimulates the intrinsic GTPase
activity of Ga 12 and Ga 13 (Kozasa et al., 1998) (Figure 1.3). Co-immunoprecipitation
experiments demonstrated a direct interaction between Ga 13 and Lsc via its RGS and DH
domains (Hart et al., 1998; Wells et al., 2002). The binding of activated Ga 13  to Lsc also
stimulate its Rho GEF activities (Hart et al., 1998). In NIH3T3 cells, Lsc and Ga 13 can
synergistically activate serum response factor (SRF) (Mao et al., 1998b), and in
astrocytomas, over-expression of Lsc is involved in cell rounding induced by thrombin
stimulation and the overexpression of Ga 12 (Majumdar et al., 1999). Based on these
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observations, it was postulated that Ga 12 and Ga 13 activates Lsc, which then catalyzes
RhoA activation, leading to SRF-dependent transcriptional activation. As Lsc is specifically
expressed in the hematopioetic system, it remains uncertain whether conclusions derived
from ectopic expression studies in non-lymphoid cells can be extended to lymphocytes.
Of interest is that Lsc assumes both positive and negative regulatory functions mediated by
its GEF domain and RGS domain respectively. How these two branches of signal integrate
remains an open question. One possibility is that Lsc down-regulates its own activation, thus
generating only short live signals. Experiments with Lsc mutants carrying mutations in the
GEF or the RGS domains may resolve these issues.
Lsc is shown to act downstream of Ga 12 and Ga 13 coupled receptors (Kozasa et al., 1998)
(Girkontaite et al., 2001). One such receptor is the lymphoid-expressed G-protein coupled
receptor (GPCR) G2A, a receptor that mediates actin rearrangement in a Ga 13-dependent
manner in murine embryonic fibroblasts (Kabarowski et al., 2000). Another set of receptors
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Figure 1.3. Primary structures of p115 Lsc. These include a regulator of G 
protein signaling (RGS) domain which stimulate the intrinsic GTPase activity 
of Ga 12 and Ga 13 and a PH (pleckstrin homology) domain and a Dbl 
homology (DH) domain, which catalyzes guanine nucleotide exchange for 
RhoA. Ligands of several Ga 12/13 couple receptors are indicated.
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that signal through Ga 12/13 include lysophospholipid receptors (Fukushima et al., 2001),
and receptors for sphingosine-1-phosphate (Pyne and Pyne, 2000), thrombin (Majumdar et
al., 1999), and thromboxane A2 (TXA2) (Djellas et al., 1999). The function of these molecules
in lymphocytes remain largely obscure, with the exception of G2A, which regulates
lymphocyte homeostasis (Le et al., 2001).
Although Ga 12/13 are known to mediate crucial functions of platelets (Klages et al., 1999),
their roles in hematopoietic cells is unclear. Some evidence suggest that Tec family kinases
such as Tec, Bmx and BTK act downstream of Ga 12/13 (Jiang et al., 1998; Mao et al.,
1998a). Several Tec family kinases play vital roles in immune system. BTK is a crucial
regulator of B cell development and activation, whereas Itk/Emt and Rlk/Txk are involved in
activation and maturation of T cells (Schaeffer and Schwartzberg, 2000; Yang et al., 2000).
The fact that Ga 12/13 act upstream of Tec family kinases, and that these kinases regulate
immune responses suggest that other downstream effectors of Ga 12/13, such as Lsc, may
also modulate immune functions.
First evidence for a function of Lsc in lymphocytes came from analysis of Lsc-/- mice
(Girkontaite et al., 2001). These mutant mice have a reduced number of marginal zone B
(MZB) cells in the spleen and reduced numbers of recirculating (B220hiIgMlo) B cells in the
bone marrow. They also exhibit a defective humoral responses to TI and TD antigens.
Furthermore, Lsc-/- T and B cells show a decrease in LPA- and TXA2-induced actin
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polymerization, thus providing direct genetic evidence that Lsc acts downstream of Ga 12/13
coupled receptors in remodeling of the cell cytoskeleton. Interestingly, Lsc mutant T and B
cells also show a reduced basal migration in a transwell migration assay. Together these
data indicate that Lsc is a positive regulator of homing or maturation of MZB cells and
recirculating B cells, actin polymerization mediated by Ga 12/13 coupled receptors, and basal
motility of T and B cells. These positive regulatory roles are likely mediated by the GEF
domain of Lsc which catalyses the activaton of Rho GTPases. Lsc also has a negative
regulatory role in the immune system. This is highlighted by the observation that Lsc-/- lymph
node T cells display an increase basal proliferation (Girkontaite et al., 2001). In addition,  Lsc-
/- MZB cells exhibit enhanced migration after serum activation. On a molecular level, the
negative regulatory role of Lsc is probably executed by the RGS domain which may be
involved in GPCR desensitization. Further experiments are required to define the signaling
pathways downstream of Lsc in lymphocytes.
1.6 Aimes of the project
Rho GTPase are important regulators of a variety of cellular functions and they are
implicated in NK cell mediated cytotoxicity. However, until now, there is no genetic evidence
for the role of Rho GTPases and GEFs in the development and the activation of NKT and NK
cells. The aims of this project were to characterize the functions of the GTPase activators
Vav-1, Vav-2 and Lsc/p115 Rho GEF in NKT and NK cell development and activation. I took
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advantage of Vav- and Lsc-deficient mice generated in the laboratory to address whether
Vav-1 and Vav-2 are involved in the maturation of NK and NKT cells and in the induction of
spontaneous cytotoxicity and ADCC of murine NK cells. In addition, since Vav-1 and Vav-2
can compensate each other in B cell development, I wanted to examine whether this
compensation is extended to the ontology of NK and NKT cells and the activation of NK cells.
Finally, since Lsc is expressed in LAK cells, this study investigated whether Lsc is also
expressed in freshly purified NK cells and whether it has a role in the development of NK and
NKT cells and NK cell cytotoxicity.
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2. Materials and Methods
2.1 Mice
The generation of Vav-1, Vav-2, and Vav-1/Vav-2 deficient mice is described elsewhere
(Fischer et al., 1998a; Tedford et al., 2001). All Vav mutant mice were crossed onto a
C57BL/6 mouse background for 8-9 generations. Mice were maintained under pathogen-free
conditions in accordance with institutional guidelines and were used at 8-12 weeks of age.
Lsc-/- mice (Girkontaite et al., 2001) were on an 129 background and used for experiments at
the age of 9-12 weeks.
2.2 Cell lines
See Table 2.1 for a list of cell lines. All cell lines were grown in RPMI 1640 and 10% FCS.
2.3 Antibodies
See Table 2.2 for a list of antibodies. To generate anti-CD4 and anti-CD8 antibodies,
hybridomas were grown in RPMI 1640, 10% FCS, Glutamine, penicillin and  streptomycin.
Cell free supernatants were harvested when the medium turns slightly yellow. Optimal
concentrations of antibodies used in experiments were determined by incubating with 100 m l,
300 m l or 500 m l of antibody supernatant for 30 minutes on ice. The cells were washed and
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subjected to complement lysis for 50 minutes at 37°C. The efficiency of purification was
determined by FACS analysis of CD4+ and CD8+ cells. A normal spleen contains around 30-
40% CD3+ cells. After complement lysis, this is reduced to 2-5%.
2.4 Tissue harvesting and cell culture
2.4.1 Splenectomy
The mice were sacrificed by cervical dislocation.  Mice were placed on their right side and an
incision was made on the left side skin with a pair of scissors.  The incision was made
approximately 2.5 cm long, from between the last rib and the hip joint.  Another incision (1-2
cm) was made in the peritoneal wall and the spleen, a red enlongated bean-shape organ,
was pulled onto the exterior wall.  The spleen was removed by cutting off the mesentery and
connective tissues attaching the spleen to the abdominal cavity.
2.4.2 Splenic NK cells enrichment
Single cell suspensions were generated by incubating 3-5 ml of 0.16 M ammonium chloride
for 2-5 minutes at room temperature to lyse erythrocytes. The incubation was terminated with
5 ml of cold RPMI 1640 and cells were spun down. Cell pellets were resuspended in 2 ml of
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Table 2.1 Cell lines
Cell lines MHC Class I Source Comments
C4.4.25
EL4
RMA
RMA/S
YAC-1
H-2b
H-2b
H-2b
H-2b
H-2a
C57Bl/6 T lymphoma
C57Bl/6 T lymphoma
C56Bl/6 T lymphoma
C56Bl/6 T lymphoma
A/Sn lymphoma
C4.4.25 is derived from EL4 by selecting MHC
class I- variant of EL4 (Glas et al., 1992).
EL4 was established from a lymphoma induced
in a C57Bl/6 mouse by 9,10-dimethyl-1,2-
benzanthracene (Gorer, 1950). They are CD4-
CD8-.
RMA cells were derived from RBL-5, a
Raucscher virus-induced T lymphoma (Ljunggren
and Karre, 1985). RMA cells were used for
ADCC because they are resistant to NK- and
LAK-mediated spontaneous cytotoxicity.
RMA/S is derived from RMA by selecting MHC-
class I- variant of RMA (Ljunggren and Karre,
1985). It is a putative target for NK cytotoxictiy in
vitro and in vivo.
YAC-1 is a lymphoma which was induced by
inoculation of the Moloney leukemia virus (MLV)
into a newborn A/Sn mouse (Kiessling et al.,
1975). The cells are sensitive to NK- and LAK-
mediated spontaneous cytotoxicity.
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Table 2.2 Antibodies
Antibodies against Source Clone Dilutions Assay
anti-mouse HRP
anti-mouse HRP
CD3
CD3
CD4
CD8
CD16/CD32 (FcR)
CD16/CD32 (FcR)
CD44
CD45
CD69
DX5
ERK
pERK
FasL
HSA
IFNg
IFNg (biotinylated)
IL-2Rb
IL-4
IL-4 (biotinylated)
JNK
pJNK
Lsc
Ly49D
Ly49G2
NK1.1
p38
pp38
streptavidin alkaline phosphate
streptavidin-APC
streptavidin-Cy-chrome
streptavidin-PerCP
TNF a
TNF a (biotinylated)
Vav-1
Vav-2
Amersham
Amersham
Pharmingen
Purified antibodies
T. Winkler (Germany)
T. Winkler (Germany)
Pharmingen
Purified antibodies
Pharmingen
Pharmingen
Pharmingen
Pharmingen
Santa Cruz
Santa Cruz
Pharmingen
Pharmingen
Pharmingen
Pharmingen
M.Miyasak (Japan)
Pharmingen
Pharmingen
Pharmingen
Pharmingen
(Girkontaite et al., 2001)
Pharmingen
Pharmingen
Pharmingen
Santa Cruz
NEB
Amersham
Pharmingen
Pharmingen
Pharmingen
Pharmingen
Pharmingen
UBI
M. Barbacid (Spain)
cat. nr. NA 9340
cat. nr. NA 931
145-2C11
145-2C11
172
31M
2.4G2
2.4G2
IM7
16A
H1.2F3
DX5
K-23
E4
MFL3
M1/69
R4-6A2
XMG1.2
rabbit polyclonal
11B11
BVD4-1D11
G151-666
cat. nr.9251
Lsc24
4E5
LGL-1
PK136
C-20
cat nr. 9211
-
-
-
-
G281-2626
MP6-XT3
cat. nr. 05219
BR82a
1:10000
1:10000
1:200
2 m g
300 m l/spleen
300 m l/spleen
1:200
1:50
1:200
1:200
1:200
1:200
1 m g/ml
1 m g/ml
1:200
1.200
1 m g/ml
0.666 mg/ml
1:200
1 m g/ml
0.5 m g/ml
0.1 m g/ml
1:1000
0.1 m g/ml
1:200
1:200
1:200
0.1 m g/ml
1:1000
1:2000
1:200
1:200
1:200
2 m g/ml
1 m g/ml
0.1 m g/ml
1:5000
Western blot
Werstern blot
FACS
Injection
complement lysis
complement lysis
FACS
Blocking FcR (FACS)
FACS
FACS
FACS
FACS
Western blot
Western blot
FACS
FACS
ELISA
ELISA
FACS
ELISA
ELISA
Western blot
Western blot
Western blot
FACS
FACS
FACS
Western blot
Western blot
ELISA
FACS
FACS
FACS
ELISA
ELISA
Western blot
Western blot
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pre-warmed RPMI 1640 with 10% FCS.  This suspension was pipetted into nylon wool (NEN)
columns, which has been pre-saturated with RPMI 1640 and 10% FCS for 1 hour at 37°C.
After the cell suspension was incubated in the column for 1 hour at 37°C, pre-warmed
medium is added into the column to displace unattached cells. Cells were eluted with 15 ml
of medium, spun down and resuspended in rat anti-mouse CD4 (clone 172) and rat anti-
mouse CD8 (clone 31M) antibodies (0.3 ml/spleen). The cells were stained for 30 minutes at
4°C before washed and incubated with baby rabbit complement (Cederlane, 0.5 ml/spleen)
for an additional 50 minutes at 37°C. The remaining cells were either used directly used in
cytotoxic assay or they were cultured to generate LAK cells. LAK cells were generated by
incubating enriched splenocytes for 6 days in 6-well plates with 2 ml of complete medium
(RPMI 1640, 10% FCS, Glutamine, penicillin, streptomycin, 5 x 10-5 M 2-mercapto-ethanol)
and 10% supernatant from X63-Ag8-653 plasmacytoma cells expressing recombinant mIL-2
cDNA (Karasuyama and Melchers, 1988).  New IL-2 (10% of total volume) is added every
two to three days.  At day 6, LAK cells were harvested and the purity of CD3-NK1.1+ cells
was determined by FACS analysis. The optimal concentration of IL-2 supernatant was
determined by incubating splenocytes with 5%, 10% or 20% of IL-2 supernatant for 6 days.
Titration that yield the highest purity of CD3-NK1.1+ cell (96-98%) with minimum doses of IL-2
were used.
2.4.3 Thymectomy and thymocyte preparation
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The mice were sacrificed by cervical dislocation and were placed on their back.  A small
incision was made in the skin just over the second and the third rib with a pair of scissors.
The incision was elongated toward the clavicles. Once the chest cavity was exposed, an
another incision was made along both sides of the sternum. The sternum was cut away,
exposing the heart and the lungs.  The white lobed tissue located under the ribs, on top of
the hearts and toward the head is the thymus. This was pulled away with a pair of forceps.
The thymi were meshed with a 5 ml syringe plunger. The tissues were washed with 10 ml of
RPMI 1640.
2.4.4 Harvesting liver lymphocytes
Solutions:
I. 100% Percoll: Dilute 90% stock Percoll solution (Pharmacia) with 10% 10x PBS.
II. 40% Percoll: Dilute 100% Percoll to 40% with RPMI 1640 + 5% FCS.
III. 80% Percoll: Dilute 100% Percoll to 80% with RPMI 1640 + 5% FCS.
The abdominal cavity was opened and the liver was flushed of blood with 3-5 ml of RPMI
1640 and 5% FCS via the portal vein. This is done by inserting a syringe into the portal vein
and injecting 3-5 ml of medium. The liver turns white once depleted of blood. The liver is
mashed with a 5 ml syringe plunger through 70 m m nylon mesh Netwells (Co-Star). Single
cell suspension was made and cells were pelleted and resuspended in 14 ml of 40% Percoll
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solution. Using a 10 ml pipette, the 40% Percoll cell suspension was carefully laid over a 6 ml
of 80% isotonic Percoll solution. The suspensions were centrifuged at room temperature for
20 min at 1000 x g with no brakes at termination. The resulting gradient consists of three
layers: the liver fat on the top layer, followed by the 40% Percoll and the 80% Percoll
containing hepatocytes and erythrocytes at the bottom. Hepatic lymphocytes reside at the
40-80% interface. The fat layer and parts of the 40% Percoll layer were aspirated away. The
lymphocytes were carefully removed with an 1 ml pipette and washed 2-3 times with RPMI
1640 and 5% FCS before they were stained and analysed by FACS.
2.4.5 Harvesting lymphocytes from the bone marrow
Femurs were removed by cutting away the skin and neighboring muscle groups.  Both ends
of the femurs were cut and the bone marrows were flushed out into an 1.5 ml eppendorf tube
by inserting an 1 ml syringe into one end of the bone. When all the marrow is flushed out, the
bone will turn white. The bone marrow cells were spun at maximum speed for 30 seconds
with a desk top centrifuge. Erythrocytes were lysed in 0.5 ml of 0.16 M ammonium chloride
solution for 2 minutes and terminated with 1 ml of cold RPMI 1640. The cells were washed 2
times with RPMI1640 before they are stained for FACS analysis.
2.5 Flow cytometry
Solution:
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I. FACS buffer: PBS, 2% FCS and 0.1% sodium azide.
Single cell suspensions (5 x 105 in 100-200 m l of FACS buffer) were obtained from the
indicated tissues and preincubated for 30 min. at 4°C with anti-CD16/CD32 (clone 2.4G2) in
FACS buffer to block FCg RII/III receptors. Cells were washed and stained with the following
antibodies: FITC- or biotin-labeled anti-CD3 mAb (clone 2C11), PE-labeled mAb anti-NK1.1
(clone PK136), biotin-labeled anti-HSA (clone M1/69), PE-labeled DX5, FITC-labeled anti-
CD45 (clone 16A), FITC-labeled anti-CD44 (clone IM7), anti-b 1 integrin (clone Ha2/5), biotin-
labeled anti-IL-2Rb  (gift of T. Tanaka and M. Miyasaka, Japan), biotin-labeled anti-CD69
(clone H1.2F3), FITC-labeled anti-CD16/CD32 (clone 2.4G2), FITC-labeled anti-Ly49D
(clone 4E5), FITC-labeled anti-Ly49G2 (clone LGL-1) and biotinylated anti-FasL (clone
MFL3). For samples stained with biotin-labeled antibodies, the primary antibodies were
washed away with 500 m l of FACS buffer. Cells were spun down for 5 minutes at 1200 rpm
before resuspended in 200 m l of FACS buffer. Biotinylated antibodies were visualized with
streptavidin-Cy-chrome, streptavidin-APC or streptavidin-PerCP. Labeled cells were washed
with 500 m l of FACS buffer and spun down for 5 minutes at 1200 rpm. The cells were
resuspended in 500 m l of FACS buffer before analysed with FACScalibur (Becton Dickinson)
and quantified with CellQuest software. Unless stated otherwise, all antibodies used for
FACS analyses were purchased from Pharmingen.
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2.6 In vivo injection of anti-CD3
Mice were intravenously injected with 2 m g of anti-CD3 antibodies in 500 m l of PBS. Ninety
minutes after anti-CD3 treatment, splenocytes were harvested and resuspened in complete
medium (RPMI 1640, 10% FCS, Glutamine, penicillin, streptomycin, 5 x 10-5 M 2-mercapto-
ethanol). They were plated in triplicates (62.5 – 1000 x 104 cells per well) in 96 well plate for
1.5 hr. at 37°C. Supernatants (50 m l) were harvested and subjected to ELISA.
2.7 ELISA
Solutions:
I. Coating buffer for IL4 and IFN: 0.1 M Na2HPO4, adjust to pH 9.0 with 0.1 M
NaH2PO4.
II. Coating buffer for TNF : 0.1 M Na2HPO4, adjust to pH 4.35 with 0.1 M NaH2PO4.
II. Blocking buffer: PBS with 10% FCS and 0.1% sodium azide.
IV. Washing buffer: PBS with 0.05% Tween-20.
V. Substrate solution: 0.2 g/ml 4-nitrophenyl phosphate disodium salt (Serva) in AP-
substrate buffer.
VI. AP-substrate buffer: 900 ml H2O, 97 ml diethanoamine (Sigma), 0.1 ml 10% NaN3,
0.1g MgCl2.6H2O, pH 9.8 (HCl).
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Capturing antibodies for IL-4 (clone 11B11, Pharmingen, final concentration: 1 m g/ml), IFNg
(clone R4-6A2, Pharmingen, final concentration: 1 m g/ml) and TNFa  (clone G281-2626,
Pharmingen, final concentration: 2 m g/ml) were diluted in coating buffer. This solution (50 m l)
were placed in ELISA plates (Nunc-ImmunoTM MaxiSorpTM) overnight in the dark at 4°C. The
coating solution was removed and the plates were incubated with 150 m l per well with
blocking buffer for 1 hour at room temperature.  The plates were washed three times with 0.2
ml/well of washing buffer before 50 m l of undiluted culture supernatants were applied to the
plates and incubated at 4°C overnight in the dark.  The supernatants were decanted and the
plates were washed three times in washing buffer. Detecting antibodies (50 m l) diluted in
blocking buffer were added (anti-IL-4, clone BVD4-1D11, final concentration 0.5 m g/ml; anti-
IFNg , clone XMG1.2, final concentration 0.666 m g/ml; and anti-TNFa  final concentration 1
m g/ml).  The detecting antibodies were incubated for 1 hour at room temperature and the
plates were washed three times in washing buffer.  50 m l of streptavidin alkaline phosphatase
(Amersham, dilution 1:2000) were added and incubated for an additional one hour. The
plates were washed ten times in washing buffer and 100 m l of substrate solution was added.
The reactions were developed in the dark at room temperature until the color turned yellow.
The absorbance was measured at 405 nm on a Microplate Reader (Metertech). Standards
for IL-4, IFNg  and TNFa  were obtained from Biozol and diluted in blocking buffer. The
standards were in duplicates and their concentrations ranged from 10 pg/ml to 8000 pg/ml.
Background values were those wells coated with blocking buffer and contained no culture
supernatant. Approximately 500 pg/ml of IL-4 and 7000 pg/ml of IFNg  were detected in the
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supernatants from 107 stimulated splenocytes.
2.8 Cytotoxic assays
2.8.1 Spontaneous cytotoxicity
Splenocytes freshly isolated x vivo can spontaneously lyse tumors without prior stimulation.
This activity is mediated by NK cells. Cytototoxic activities can be greatly enhanced by
culturing NK cells in IL-2 or IL-18 to generated LAK (lymphokine activated killer) cells
(Trinchieri, 1989). This is likely due to the up-regulation of many death-inducing receptors
during the culturing process (Kayagaki et al., 1999). To assay NK cytotoxicity, I used tumors
targets purchased from ATCC, and one cell line, C4.4.25, from H. G. Ljunggren (Sweden).
NK cells were either cultured in IL-2 for 6 days to generate LAK cells or they were directly
used after the depletion of splenic CD4+ and CD8+ cells. FACS analysis confirmed the lack of
CD3+ T cells and CD3+ NK1.1+ NKT cells in freshly purified effector cell populations. NK cells
were tested against tumor targets as indicated in the text. Target cells (1 - 5 x 106 in 200m l of
RPMI 1640) were labeled in a 15 ml tube with 51Cr (100 m Ci, Amersham) for 60 min at 37°C.
Cells were washed four times with 10 ml of RPMI 1640 and resuspended in complete
medium (RPMI 1640, 10% FCS, Glutamine, penicillin, streptomycin, 5 x 10-5 M 2-mercapto-
ethanol) at a concentration of 105 cells/ml.  100 m l of this cell suspension were placed in each
well of a V-bottom 96-well plate (Sarstedt). NK or LAK effectors were harvested and
resuspended in complete medium. 100 m l of effectors were added into wells with 100 m l of
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targets. For LAK effectors, the E:T (effector:target) ratios were 30:1, 10:1, 3:1. For freshly
purified effectors, E:T ratios were 100:1, 50:1, and 25:1. Triplicates were carried out for each
ratio value. The plates were placed in an incubator at 37°C for 4 hours. Spontaneous cell
lysis and maximum cell lysis were determined with 104 cells in medium alone and 1% TX-100
respectively. After 4 hours at 37°C, samples were centrifuged for 5 minutes at 1200 rpm and
50 m l of the supernatants were transferred in a gamma counter to determine 51Cr release.
Percentage of specific lysis was calculated with the formula: % sample specific lysis =
[(sample counts-spontaneous counts)/(maximum count-spontaneous counts)] x 100%
2.8.2 ADCC
CD16 (or FcRg III) on NK cells can mediate tumorcidal activity. In the presence of anti-tumor
antigen antibodies, the Fc portion can ligate FcRg III on NK cells, leading to their activation
and the subsequent lysis of tumor targets. To access CD16-mediated target lysis (ADCC), I
used RMA cells as target cells. These cells are resistant to NK spontaneous cytotoxicity, but
they can be readily lysed in the presence of antibodies against cell surface antigens such as
Thy1.2. RMA cells were labeled with 51Cr and washed as described in 2.8.1. Cells (1x106)
were resuspended in 1 ml of RPM I640 and incubated with 0.5 m g anti-Thy 1.2 antibodies for
0.5 hour at 4°C. A control sample were incubated with medium. The cells were washed once
with 10 ml of RPMI 1640 and resuspended in a concentration of 105/ml. 0 m l of this cell
suspension were placed in each well of a V-bottom 96-well plate. The remaining steps were
carried out as described in 2.8.1.
57
2.9 Cell stimulation
2.9.1 FcR mediated MAPK activation
Fcg RIII (CD16) cross-linking in NK cells induces the activation of ERK, JNK, and p38 kinases
(Milella et al., 1997; Trotta et al., 2000). To assess the integrity of these pathways, LAK cells
were stimulated with anti-CD16. LAK cells (5 x 105) harvested from cultures described in
2.4.2. were incubated with 4 m g of anti-Fcg R (2.4G2, Pharmingen) for 30 min at 4°C. Cells
were washed with ice-cold PBS prior to incubation with 4 m g of rabbit anti-rat F(ab’)2
antibodies (Southern Biotechnologies) for another 30 min at 4°C to cross-link FcR receptors.
Cells were washed again, pelleted by centrifugation, and subsequently resuspended with
200 m l pre-warmed serum-free RPMI 1640.  This is denoted as the start of stimulation and
the samples were incubated at 37°C for various time points as indicated in the text.
Reactions were terminated by centrifugation and lysis in 20 m l of sample buffer (see solutions
of 2.10). These were subjected to Western blot analysis described in 2.10.
2.9.2 Stimulation of NK cells with tumor targets
Tumor cells are rapidly lysed upon contact with NK cells. To assess marker upregulation and
cytokine production during NK cell-tumor cell engagement, splenocytes depleted of CD4+
and CD8+ cells as described in 2.4.2. were incubated with YAC1 cell at a E:T ratio of 100:1
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for the indicated time points at 37°C with conditions described in 2.8.1. Cells were
subsequently harvested for FACS analysis described in 2.5. Supernatants from the culture
were taken for ELISA as described in 2.7.
2.10 Western blot analysis
Solutions:
I. 2x sample buffer: 2.5 ml of  0.5 M Tris-HCl, pH6.8; 4 ml 10% SDS, 2 ml of glycerol,
0.5 ml of mercaptoethanol and 0.05% bromophenol blue in 10 ml.
II. 10x SDS PAGE running buffer: 29 g Trizma Base, 14 g Glycine, 10 g SDS in 1 L.
III. Transfer buffer: 3.03 g Trizma-base, 14.4 g glycine, 100 ml methanol in 1 L.
IV. Western blocking buffer: 5% BSA or 5% skim milk in 1x TBS-T.
V. 10x TBS-T: 48.4 g Tris, 160 g NaCl, 20 ml Tween-20, pH 7.6 in 2 L.
VI. Stripping buffer: 62.5 mM Tris-Hcl pH 6.7, 2% SDS, 100 mM 2-mercaptoethaneol.
Protein samples were boiled for 2 min and briefly spun down before they are loaded in
acrylamide gel.  The gels were run in 125 v for 1.5 hour with 1x SDS PAGE running buffer.
The proteins were transferred onto HybondTM-P membranes (Amersham) with Semi-Dry
Transfer cell (Bio-Rad). The blots were blocked 1 hour with blocking buffer and were washed
three times with 1 x TBS-T. Primary antibodies anti-pERK and anti-ERK (Santa Cruz), anti-
pJNK (NEB), anti-JNK (NEB), anti-pp38 (NEB), anti-p38 (NEB), anti-Vav-1 (UBI), and anti-
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Lsc (Girkontaite et al., 2001) were incubated for an additional 1 hours followed by anti-mouse
HRP or anti-rabbit HRP (Amersham), and detection by ECL (Amersham) in accordance with
manufacturer’s instructions.  Western blots were stripped in 50 ml of stripping buffer at 50°C
water bath for 30 min and were washed three times in 100 ml of washing buffer before re-
probed with antibodies indicated in the text.
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3. Results
3.1 Development of NK and NK T cells in Vav-1-deficient mice
Vav-1 is a critical regulator for T cell development and activation. Since T cells and NK cells
share a common progenitor (Sanchez et al., 1994), I reasoned that Vav-1 could also be
important for NK cell maturation. Therefore I stained various lymphocyte populations from
Vav-1-/- mice with antibodies against CD3 and NK1.1 to detect NK and NK T cell populations.
To eliminate non-specific background, I gated on mature cells which are HSAlo (Allman et al.,
1992; Crispe and Bevan, 1987). I observed no difference in relative and absolute numbers of
bone marrow, splenic and hepatic NK cells between wild type and Vav-1-/- mice (Figure 3.1A
and B). Similar results were obtained when I stained NK cells with DX5, another putative NK
cell surface marker (Figure 3.1C). I examined surface expression of markers on splenic NK
cells and found normal expression of CD45, CD44, b 1 integrin, IL-2Rb , CD69 and FcRg III/II
in Vav-1-/- NK cells (Figure 3.1D). In addition to the severe paucity of thymic and peripheral T
cells, however, I observed a gross reduction of thymic, bone marrow, splenic and hepatic NK
T cells in Vav-1-/- mice (Figure 3.1A and B). A decrease in NKT cells in the thymus and the
liver was also evident using DX5 as a NK marker (Figure 3.1C). However, in the spleen,
there was only a marginal decrease in CD3+DX5+ cells in mutant animals (Figure 3.1C). This
might be due to that fact that only selective splenic NKT cells express DX5, and therefore
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Figure 3.1 A. NK and NK T cell development in Vav-1-/- mice 
characterized by CD3 and NK1.1 surface expression. 
Immunofluorescence analysis of thymic, bone marrow, splenic and 
hepatic NK and NK T cells. Cells were isolated from 8-9 wks-old 
wildtype and Vav-1-/- mice and stained with anti-CD3-FITC, anti-
NK1.1-PE and anti-HSA-biotin antibodies followed by Cy-chrome 
streptaviden to detect biotinylated antibodies. To visualize NK and 
NK T cells gates were set on HSAlo cells. One result representative 
of 5 experiments is shown. 
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Figure 3.1 B.  Absolute numbers of T, NK T and NK 
cells. Cells from 3 wild type and 3 Vav-1-/- mice were 
stained as in A. The mean results (+ standard 
deviation) are shown (Student’s t test: thymus 
p<0.005, bone marrow p<0.05, spleen p<0.05, liver 
p<0.05)
C
e
ll 
n
u
m
b
e
r 
( 
x
 1
0-6
 )
63
A
WT Vav1-/-
C
D
3
DX5
Liver
39.7 9.211.6 3.2
2.7 2.9
Thymus
100 101 102 103 1041
00
1
01
1
02
1
03
1
04
100 101 102 103 1041
00
1
01
1
02
1
03
1
04
1.2 0.2
Spleen
100 101 102 103 1041
00
1
01
1
02
1
03
1
04
34.3 9.63.3 2.7
2.8 3.3
100 101 102 103 1041
00
1
01
1
02
1
03
1
04
100 101 102 103 1041
00
1
01
1
02
1
03
1
04
100 101 102 103 1041
00
1
01
1
02
1
03
1
04
Figure 3.1 C. NK and NK T cell development in Vav-1-/- mice 
characterized by CD3 and NK1.1 surface expression. 
Immunofluorescence analysis of thymic, splenic and hepatic NK 
and NK T cells. Cells were isolated from 8-9 wks-old wildtype and 
Vav-1-/- mice and stained with anti-CD3-FITC, anti-DX5-PE and 
anti-HSA-biotin antibodies followed by Cy-chrome streptaviden to 
detect biotinylated antibodies. To visualize NK and NK T cells gates 
were set on HSAlo cells. One result representative of 5 experiments 
is shown. 
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Figure 3.1 D. Expression of NK cell receptors on splenic NK cells. 
Splenocytes were stained with anti-CD3, anti-NK1.1, and 
antibodies against the indicated markers. Histograms for wild type 
(closed histogram) and Vav-1-/- (opened histogram) NK cells were 
generated by gating on CD3-NK1.1+ populations. One result 
representative of 2 experiments is shown.
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total numbers of NKT cells are under-represented by the CD3+DX5+ stain (Eberl et al.,
1999b). Together, these data indicate Vav-1 is required for NKT cell development.
NKT cells are noted for their ability to rapidly secret large amount of IL-4 and IFNg  i
response to in vivo administration of CD3 (Chen et al., 1997; Leite-de-Moraes et al., 1995;
Mendiratta et al., 1997; Yoshimoto and Paul, 1994). To determine whether Vav-1-/-
splenocytes retain the capability to produce these cytokines following CD3 activation, anti-
CD3 antibodies were injected intravenously into wild type and Vav-1-/- mice and ninety
minutes later splenocytes were seeded from injected mice at various densities and cytokine
production was measured after a  90 min. incubation. I observed an approximate 90%
reduction in IL-4 and IFNg  secretion by Vav-1-/- splenocytes compared to wild type (Figure
3.2). These data indicate that Vav-1 is not necessary for mainstream NK cell development,
but is indispensable for NK T cells.
3.2 Vav-1 is not required for ADCC and CD16-mediated MAPK activation
NK cells use their low-affinity Fcg RIIIA to form conjugates with antibody-coated cells. Once
NK cells are bound to a target cell, they activate their ADCC responses. Ectopic expression
of Vav-1 in human NK cells potentiates ADCC (Billadeau et al., 1998), while inhibition of Vav-
1 expression with anti-sense oligonucleotides markedly reduced Fcg R mediated cytotoxic
activity (Galandrini et al., 1999). To determine whether Vav-1 is necessary for ADCC of
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murine NK cells, I performed NK cell cytotoxicity assays. Since freshly isolated NK cells
exhibit only minimal cytotoxicity against most target cells, I removed B cells, CD4+ and CD8+
T cells from splenic cell suspensions, and generated lymphokine activated killer (LAK) cells
in vitro in the presence of IL-2. After culturing for 6 days, the purity of both wild type and Vav-
1-/- NK cells (CD3-NK1.1+) cells was over 96% and no significant contamination of CD3
expressing NKT cells was observed as judged by FACS analysis (Figure 3.3A). Since LAK
cells generated from mutant mice were comparable in both amount and purity to those of
wild type, it is likely that Vav-1 is not necessary for NK cell proliferation. Vav-1 is present in
wild type LAK cells, but it is absent in Vav-1-/- LAK cells (Figure 3.3B). I also detected Vav-1
expression in freshly purified ex vivo NK cells (Figure 3.3C). To determine whether Vav-1 is
required for ADCC in murine NK cells, wild type and Vav-1-/- LAK cells were co-cultured with
RMA target cells in the presence or the absence of anti-Thy 1.2 antibodies (Figure 3.4A).
Vav-1-/- LAK cells exhibited a reduction in spontaneous cytotoxicity against RMA cells. The
addition of anti-Thy 1.2 antibodies, however, led to the augmentation of cytotoxicity of both
wild type and Vav-1-/- NK cells to the same degree, indicating that ADCC is independent of
Vav-1 function.
Ligation of CD16 (FcRg III) in human NK cells leads to rapid tyrosine phosphorylation of Vav-1
(Billadeau et al., 1998; Galandrini et al., 1999), implicating Vav-1 as a downstream target.
CD16 cross-linking in NK cells also induces the activation of ERK, JNK, and p38 kinases
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Figure 3.3. Vav-1 expression in pure NK cells 
populations. A. Purity of cultured primary NK cells. 
Splenocytes were subjected to nylon wool passage 
and complement lysis of CD4+ and CD8+ cells before 
they were cultured for six days in the presence of IL-2. 
Aliquots from cultured or ex vivo  splenocytes were 
stained with FITC-conjugated anti-CD3 and PE-
conjugated NK1.1 mAbs. B. Splenic cells were 
labeled as indidcated in A and were FACS sorted for 
CD3-NK1.1+ population. C. Expression of Vav-1 in 
primary NK cells. Cell lysates of wild type sorted NK 
cells and cultured NK cells from Vav-1+/+ and Vav-1-/-
mice were subjected to Western blot analyses. 
Detection of protein expression was performed with 
anti-Vav-1, anti-Vav-2 and anti-ERK antibodies as a 
loading control.
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Figure 3.4. ADCC and CD16-mediated MAPKs activation of Vav-1-/- NK cells. A.
ADCC. Cultured NK cells were distributed in triplicates into plates containing 51Cr-
labeled RMA targets at the indicated effector:target ratio. RMA cells were 
incubated for 1 hour at room temperature with anti-Thy1.2 culture supernatant or 
medium alone. Percentage of specific lysis was determined by the amount of 
chromium released at 4 hours. B. MAPK-activation. Cultured NK cells were 
stimulated with anti-CD16/CD32 and cross-linked with rabbit anti-rat antibodies. 
Cell lysates were resolved with SDS-PAGE and immunoblotted with the indicated 
antibodies. Results are representative of three independent experiments.
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(Milella et al., 1997; Trotta et al., 2000). To determine whether Vav-1 plays a role CD16-
mediated MAPK activation, Western blot analysis was performed with lysates from NK cells
stimulated with anti-CD16 antibodies or with medium alone (Figure 3.4B). Consistent with
published results, ligation of CD16 activates ERK, JNK, and p38. In both wild type and Vav-1-
/- LAK cells, activation of ERK and JNK was sustained after 20-30 min, while the levels of
active p38 reached a plateau at 2-5 min, and declined to background level by 15 min. The
expression of CD16 was comparable between wild type and Vav-1-/- LAK cells (data not
shown). These results indicate that Vav-1 is dispensable for CD16 mediated MAPKs
activation in murine NK cells.
3.3 Spontaneous cytotoxicity is compromised in Vav-1-/- NK cells
NK cells exhibit spontaneous cytotoxicity towards some tumors cell lines. Since co-
incubation of NK cells with target cells also leads to Vav-1 phosphorylation (Billadeau et al.,
1998; Galandrini et al., 1999), Vav-1 is believed to play an important role in this process.
Furthermore, human NK cell cytotoxic activity against K562 cells is potentiated by over-
expressing Vav-1 (Billadeau et al., 1998), while reduction of Vav-1 expression by anti-sense
oligonucleotides markedly reduces NK cell cytotoxic activity (Galandrini et al., 1999). To
assess the role of Vav-1 in spontaneous cytotoxicity, I tested the ability of wild type and Vav-
1-/- NK cells to lyse a panel of target cells. Freshly isolated NK cells were obtained from
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Figure 3.5. Impaired natural cytotoxicity of freshly isolated Vav-1-/- 
NK cells. Freshly purified splenocytes depleted of CD4+and CD8+
were used as effectors against EL4 and YAC1 cells in a standard 
chromium release assay. Percentage of specific lysis was 
determined by the amount of chromium release at 4 hours. Results 
are representative of three independent experiments.
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splenocytes depleted of CD4+- and CD8+-expressing lymphocytes. I found that Vav-1-/- NK
effector cells displayed a consistently reduced ability to lyse YAC-1 cells (Figure. 3.5).
Neither wildtype nor Vav-1-/- effectors showed cytotoxicity against syngenic targets such as
EL4 cells and RMA and their respective MHC class I-deficient variants, C4.4.25 cells, and
RMA/S cells (Figure. 3.5 and data not shown). In order to compare cytotoxic abilities of
freshly isolated Vav-1-/- NK cells with those of LAK cells, I tested wildtype and Vav-1-/- LAK
cell cytotoxicity against the same targets—EL4, C4.4.25, RMA and RMA/S cells. Whereas
wildtype LAK cells developed cytotoxic capacity against these target cells, Vav-1-/- LAK cells
failed to mount strong cytotoxic responses (Figure. 3.6). Interestingly, Vav-1-/- LAK cells were
able to normally lyse YAC1 cells, indicating that freshly isolated NK cells and LAK cells have
different requirements for Vav-1. Vav-1+/- and wildtype exhibited indistinguishable cytotoxic
activity against all target cells (data not shown). Taken together, these data show that Vav-1
is important for NK cell spontaneous cytotoxicity.
3.4 Development of NK and NK T cells in Vav-2- and Vav-1/Vav-2 deficient mice
Although the above experiments have highlighted the importance of Vav-1 in many NK
activation processes, many others such as CD16 mediated ADCC and MAPK activation
seem to be independent of Vav-1. Furthermore, remnant spontaneous activity can be
observed with Vav-1-/- effectors. These raise the possibility that other Vav family members,
such as Vav-2 could compensate for Vav-1 function. Vav-2 is expressed in NK cells (Figure
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Figure 3.6.  Impaired natural cytotoxicity of Vav-1-/- IL-2-
activated NK cells. Cultured NK cells were harvested and 
chromium release assays using YAC1, EL4, C4.4.25, 
RMA, and RMA/S as targets were carried out. Percentage 
of specific lysis was determined by the amount of 
chromium release at 4 hours. Results are representative of 
three independent experiments. 
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3.3) and it is structurally similar to Vav-1 (Bustelo, 2000). It was also implicated to participate
in both NK cell natural cytotoxicity and ADCC since FcR ligation leads to Vav-2
phosphorylation and ectopic expression of Vav-2 increases NK cell natural cytotoxicity and
ADCC (Billadeau et al., 2000). These studies however were done using human derived NK
cell lines. The function of Vav-2 in murine NK cells has not been examined, and possible
synergy of Vav-1 and Vav-2 remains to be investigated.
To determine whether Vav-2 is necessary for NK and NKT cell development, I examined
these populations from lymphoid organs of Vav-2 deficient animals. I observed no difference
in relative and absolute numbers of bone marrow, splenic and hepatic NK cells between wild
type and Vav-2-/- mice (Figure 3.7 A and B). Unlike Vav-1-/- mice, Vav-2-/- mice displayed
normal development of NKT cells, indicating that Vav-2 is not necessary for NK and NKT cell
development.
It has been shown that Vav-1 and Vav-2 can compensate for each other in B cell
development (Doody et al., 2001; Tedford et al., 2001). To determine whether such
compensation is extended to the development of NK and NKT cells, I compared these
populations from wild type and Vav-1-/-/Vav-2-/- mice. Mice deficient for both Vav-1 and Vav-2
have normal numbers of NK cells, but a reduced numbers of NKT cell population similar to
those observed in Vav-1-/- animals (Figure 3.7 A and B). Therefore, both Vav-1 and Vav-2 are
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Figure 3.7 A. NK and NK T cell development in Vav-1-/-,Vav-2-/- and Vav-1-/-Vav-2-/- mice. 
Immunofluorescence analysis of thymic, bone marrow, splenic and hepatic NK and NK T 
cells. Cells were isolated from 8-9 wks-old wildtype and mutant mice and stained with anti-
CD3-FITC, anti-NK1.1-PE and anti-HSA-biotin antibodies. To visualize NK and NK T cells 
gates were set on HSAlo cells. One result representative of 4 experiments is shown. 
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Figure 3.7 B.  Absolute numbers of T, NK T and NK 
cells of Vav mutant mice. Cells from 3 mice of each 
genotype were stained as in A. The mean results (+
standard deviation) are shown.  *Significant 
differences compared to wild are indicated 
(Student’s t test: p<0.05)
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not mutual compensatory in the development of NK cells and the remnant presence of NKT
cells in Vav-1-/- mice is not due signals mediated by the presence of Vav-2.
3.5 Vav-1 and Vav-2 are not required for ADCC and CD16-mediated MAPK activation
CD16 mediated ADCC and MAPK activation are normal in Vav-1-/- NK cells. Since Vav-2 is a
close homologue of Vav-1, it might traffic signals from CD16.  Indeed, in human NK cells FcR
ligation leads to Vav-2 phosphorylation and ectopic expression of Vav-2 potentiates NK
ADCC (Billadeau et al., 2000). To determine whether Vav-2 is required for ADCC in mouse
NK cells, I performed cytotoxic assay using Vav-2-/- effectors. Wild type and Vav-deficient
LAK cells were co-cultured with RMA target cells in the presence or the absence of anti-Thy
1.2 antibodies (Figure 3.8A). Both wild type and Vav-2-/- LAK cells exhibited low spontaneous
cytotoxicity against RMA cells. The addition of anti-Thy 1.2 antibodies, however, led to the
augmentation of cytotoxicity with all NK effectors. These data suggest that Vav-2 is not
required for ADCC. To examine whether CD16 mediate MAPK activation is Vav-2
dependent, Western blot analysis was performed with lysates from wild type and Vav-2-/- NK
cells stimulated with anti-CD16 antibodies (Figure 3.8 B). Consistent with normal ADCC, I
found that ligation of CD16 on mutant cells leads to normal activation of MAPK. Therefore,
Vav-2 is not required for CD16 mediated MAPK activation.
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Figure 3.8. A. ADCC and CD16-mediated MAPKs activation of Vav deficient NK 
cells. ADCC. Cultured NK cells were distributed in triplicates into plates containing 
51Cr-labeled RMA targets at the indicated effector:target ratio. RMA cells were 
incubated for 1 hour at room temperature with anti-Thy1.2 culture supernatant or 
medium alone. Percentage of specific lysis was determined by the amount of 
chromium released at 4 hours.  Results are representative of two experiments.
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Figure 3.8.  B. MAPK-activation of Vav mutant LAK cells. Cultured NK cells were stimulated with anti-
CD16/CD32 and cross-linked with rabbit anti-rat antibodies. Cell lysates were resolved with SDS-PAGE and 
immunoblotted with the indicated antibodies. Results are representative of two independent experiments.
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and Vav-2 are dispensable for CD16-mediated ADCC and MAPKs activation in murine NK
cells and they do not assume mutual compensatory roles in these processes.
3.6 Spontaneous cytotoxicity in Vav-2 and Vav-1/Vav-2 deficient NK cells
Vav-1 is necessary in NK spontaneous cytotoxicity against a panel of tumors targets (Figure
3.5 and 3.6). To determine whether Vav-2 also share a similar role in this process, freshly
isolated splenocytes cells from Vav-2 deficient animals were depleted of CD4+- and CD8+-
expressing lymphocytes and the remaining cells were used in a cytotoxic experiment using
YAC-1 as targets. I found both wild type and Vav-2-/- NK cells showed almost identical
cytotoxic activity (Figure 3.9). I also generated LAK cells from Vav-2 deficients animals, and
tested them against EL4, C4.4.25, and RMA/S cells (Figure 3.10). Both wildtype and Vav-2-/-
LAK cells displayed similar cytotoxic responses against these target cells, indicating Vav-2 is
not required for spontaneous cytotoxicity in murine NK cells.
The ability of Vav-2-/- NK cells to exhibit a normal cytotoxic response might be explained by
the presence of Vav-1 in fulfilling a compensatory role for Vav-2. Therefore I examined
spontaneous NK cytotoxicity of Vav-1-/-Vav-2-/- NK cells. I found that Vav-1-/-Vav-2-/- effectors
exhibit reduced cytotoxicity against YAC-1 cells to the similar degree as those observed with
Vav-1-/- effectors (Figure 3.9). Similarly, LAK effectors from Vav-1-/- and Vav-1-/-Vav-2-/- mice
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lysis was determined by the amount of chromium release at 4 hours. 
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showed indistinguishable cytotoxic responses against EL4, C4.4.25 and RMA/S targets
(Figure 3.10). All LAK cells were able to lyse YAC1 cells with similar effeciency. Taken
together, these data show that Vav-1 but not Vav-2 is important for NK cell spontaneous
cytotoxicity, and Vav-2 can not functionally compensate Vav-1 in these processes.
3.7 Analysis of NK cell function in Lsc-/- mice
Studies described above highlight the importance of Vav-1 in NK cell activation. Similar to
Vav-1, Lsc is another Rho GEF that is expressed specifically in the hematopoietic system. It
is also found in LAK cells, but its functions remain unknown (Girkontaite et al., 2001).
Consistent with its presence in LAK cells, freshly purified CD3-DX5+ NK cells also express
Lsc (Figure 3.11A). To determine whether the absence of Lsc affects NK cell development, I
stained NK cells from the spleens and the livers of wild type and Lsc-/- mice and found
comparable numbers and ratios of these populations in both mice (Figure 3.11B). Mutant NK
cells also express normal levels of Ly-49D, Ly-49G2, CD16, CD45, CD44, FasL, and CD69
(Figure 3.11C). These data indicate Lsc is not required for NK cell development.
Furthermore, in Lsc-/- mice of the C57BL/6 background, CD3+NK1.1+ splenic NKT cells were
present in normal numbers and ratios as those from the wild type mice (data not shown),
demonstrating Lsc is not required for the NKT cell development.
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Figure 3.11. A. Expression of Lsc in primary NK cells. Cell 
lysates of sorted NK cells from Lsc+/+ and Lsc-/- mice were 
subjected to Western blot analyses. Detection of protein 
expression was performed with anti-Lsc and anti-Vav-1 
antibodies as a loading control. B. Immunofluorescence 
analysis of splenic NK cells. Cells were isolated from 9-12 
wks-old wildtype and Lsc-/- mice and stained with anti-CD3-
FITC, anti-DX5-PE and anti-HSA-biotin antibodies. To 
visualize NK cells gates were set on HSAlo cells. C. 
Expression of NK cell receptors on splenic NK cells. 
Splenocytes were stained with anti-CD3, anti-DX5, and 
antibodies against the indicated markers. Histograms for 
wild type (closed histogram) and Lsc-/- (opened histogram) 
NK cells were generated by gating on CD3- DX5 + 
populations. 
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To assess NK cell function, I performed cytotoxic assay using T cell depleted splenocytes
from wild type and mutant mice against a panel of tumor targets. Wild type cells showed low
level of cytotoxic responses towards YAC1 cells and almost no response against other
targets (Figure 3.12). However, Lsc-/- plenocytes elicited a greater cytotoxic activity against
YAC1, C4.4.25 and RMA/S compare to wild type cells (Figure 3.12). Both wild type and
mutant effectors showed no tumorcidal responses against EL4. This is likely due to a rich
presence of MHC class I on the surface of these cells. Lsc+/- and wildtype NK cells exhibited
indistinguishable cytotoxic activity against all target cells (data not shown). Effectors used in
the above experiments were T cell depleted splenocytes containing NK cells, B cells and
monocytes. In order to rule out possible influence of contaminating cells, cytotoxic assays
were performed with highly purified NK cells as effectors. To this end, CD3-DX5+ cells were
FACS sorted from both wild type and mutant spleens, yielding NK cells with purity around 96-
98%. These were used to kill YAC1 tumors. Consistent with results obtained from T cell
depleted splenocytes, Lsc-/- NK cells showed higher tumorcidal activities compare to wild
types cells (Figure 3.13). Taken together, these data indicate Lsc is a negative regulator of
NK cell cytotoxic activity.
NK mediated cytotoxicity against YAC1 has been shown to be potentiated by the release of
TNF a  from NK cells (Baxevanis et al., 2000). To determine whether enhancement of
cytotoxicity in mutant NK cells due to a concomitant increase in TNFa  production, YAC-1
cells were co-incubated with T cell-depleted splenocytes from wild type and Lsc-/- mice. The
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Figure 3.12. Enhanced natural cytotoxicity of freshly isolated Lsc-1-/- NK cells. 
Freshly isolated splenocytes depleted of CD4+ and CD8+ were used as effectors 
against YAC1, C4.4.25, RMA/S and EL4 cells in a standard chromium release assay. 
Percentage of specific lysis was determined by the amount of chromium release at 4 
hours. Results are representative of three experiments.
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Figure 3.13. Enhanced natural cytotoxicity of freshly isolated Lsc-1-/- NK cells. 
Freshly purified splenocytes depleted of CD4+ , CD8+  and B220+ cells befored 
they were sorted for CD3- X5+ NK cells. These were used as effectors against 
YAC1 cells in a standard chromium release assay. Percentage of specific lysis was 
determined by the amount of chromium release after 4 hours. 
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Figure 3.14. YAC1-induced TNF a  production in wild type 
and Lsc-/- splenocytes. CD4+ and CD8+ depleted 
splenocytes were incubated with YAC1 tumors at a E:T ratio 
of 100:1 for the indicated time points. TNFa  released in the 
supernatant were determined by ELISA. 
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Figure 3.15. Neutralizing TNFa  does not block cytotoxic 
responses against YAC-1 tumors. CD4+ and CD8+ 
depleted splenocytes were incubated with YAC1 tumor 
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supernatants were harvested after 1, 2, 3, and 4 hours and the concentrations of TNFa  were
determined by ELISA. As shown in Figure 3.14, mutant splenocytes displayed a marked
increase in TNFa  secretion compared to wild type NK cells. To determine whether elevated
TNF a  secretion causes enhance tumorcidal activities in mutant cells, cytotoxic assays were
carried out in the presence of neutralize anti-TNFa antibodies (Figure 3.15). I found that anti-
TNF a  antibodies had no effects on the ability of wild type and mutant NK cells in killing tumor
targets. Furthermore, mutant cells consistently exhibited higher cytotoxic responses, even in
the presence of 15-20 m g/ml of anti-TNFa antibodies. These data argue that the mechanism
of hyper-responsive mutant NK cells is not due to the enhance secretion of TNFa  and K
cytotoxicity is likely independent of TNFa  secretion. Indeed, preliminary evidence derived
from intracellular FACS analysis indicated that TNFa  was produced by CD3-B220-DX5-Mac1+
cells, suggesting NK cells do not release of TNFa  in response to YAC1 stimulation (data not
shown). Future experiments will determine which mutant populations produce TNFa , and
whether this burst of TNFa  is a secondary response to hyper-active mutant NK cells or that
target cells directly stimulate Mac1+ cells to produce TNFa .
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4. Discussion
4.1 Vav-1 regulates the development of NKT cells and the activation of NK cells
This study shows that Vav-1-/- mice exhibit a marked reduction in NKT cells, highlighting Vav-
1 as an essential regulator of both T cell and NKT cell development. ab  cells have a
polyclonal TCR repertoire, whereas NK T cells are biased for CD1d restricted TCR usage
(Godfrey et al., 2000). Thus, the requirement for Vav-1 in selection events maybe similar
between the two lineages. Indeed, some key signaling molecules that act downstream of
TCR/CD3 are noted to play critical roles in development of NK T cells. Mice carrying
mutations in the genes of src-kinases lck and fyn  also exhibit compromised NKT cell
development (Gadue et al., 1999). In T cells, Vav-1 is implicated as a downstream effector
molecule of Lck and/or Fyn (Han et al., 1997; Huang et al., 2000). Therefore Vav-1, as a
GTP-exchange factor for Rho-GTPases, may form part in a signaling cascade linking Src-
kinase activity to the activation of Rho-GTPases in NKT cells. As T cells were also reduced
in Vav-1-/- mice, further experiments are required to determine whether the defect in NKT cell
ontogeny in Vav-1-/- mice is cell-intrinsic or partially due to secondary effect of accessory
cells in the microenvironment. My observations are in line with those made by another study
which also demonstrated a gross reduction of NKT cells in lymphoid organs of Vav-1-/- mice
(Colucci et al., 2001).
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Splenic NKT cells produce a large amount of IL-4 and IFNg  in response to in vivo CD3
stimulation. This response was largely ablated in Vav-1-/- mice, which exhibit a 10- to 12-fold
reduction in IL-4 and IFNg  production. Since the absolute number of Vav-1-/- NK T cell was
reduced 3- to 4-fold, the defect in IL-4 and IFNg production cannot be only due to diminished
numbers of NK T cells. Thus, my results highlight a possible signaling defect in peripheral
NKT cells in Vav-1-/- mice and support the notion that Vav-1 acts downstream of CD3 in NKT
cells.
The loss of CD3 mediated IL-4 and IFNg  production was also observed in NKT cell deficient
CD1d-/- mice, consistent with the model that CD1d restricted NKT cells are involved in
producing these cytokines in response to CD3 challenge in vivo (Mendiratta et al., 1997). It is
interesting that wild type splenocytes produce 10 fold more IFNg  production than IL-4 in
response to in vivo CD3 administration (Figure 3.2 and (Mendiratta et al., 1997)). In contrast,
in vitro CD3 stimulation of purified thymic and splenic NKT cells produce large amount of IL-4
but only moderate amount of IFNg  (Hammond et al., 1999). Differences between the two
models are likely due to the presence of by-standing cells that can secrete IFNg  in
splenocytes. Indeed, Carnuad et al (1999) showed in vivo challenge of mice with a GalCer, a
specific activator of NKT cells, leads to IFNg  production. This triggers further secretion of
IFNg  by NK cells. Since NK cells are capable of producing large amount of IFNg , a loss of
CD3-induced IFNg  production in Vav-1-/- mice could be attributed to a NK cell defect. This is
seem unlikely, since it was shown that Vav-1-/- NK cells produce normal levels of IFNg  in
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response to anti-2B4, anti-NK1.1, anti-CD16 and IL-12 stimulation (Colucci et al., 2001).
Taken together, the loss of NKT cells in Vav-1-/- mice leads to a gross reduction of IFNg  and
IL-4 upon CD3 challenge, which could impinge on Th1 and Th2 differentiation in these mutant
mice.  Hence, it might be interesting in the future to graft wild type and Vav-1-/- NKT cells in
CD1-/- mice and examine Th1 and Th2 responses to antigen challenge in vivo.
Despite the importance of Vav-1 in the development of T cells and NKT cells, NK cell
development was normal in Vav-1-/- mice (Figure 1 A , B, C and D). In fact, both Vav-1 and
Vav-2 were dispensable for maturation of NK cells (Figure 3.7). However, Colucci et. al.
(2001) showed an increase in NK cells in the spleen and the bone marrow of Vav-1-/- mice
(Colucci et al., 2001). It is difficult to reconcile these discrepancies. One possible explanation
might be that Colucci and co-workers used mice of B10.BR background, whereas I used
mice of C57BL/6 background.
Vav-1 has been shown to be important in eliciting CTL responses, since Vav-1-/- mice have
reduced LCMV-induced footpad swelling reactions, a process mediated by CD8+ CTLs, and
are unable to clear viruses efficiently 8 days after infection (Penninger et al., 1999). In order
to examine Vav-1-/- NK cytotoxic responses, but at the same time avoid the influences
contributed by the presence of defective CD8+ TL and NKT cells in Vav-1-/- splenic culture,
pure LAK cells were generated from both wild type and mutant mice. Cytotoxic assay using
pure LAK effectors indicated that Vav-1-/- NK cells exhibited reduced efficiency in killing EL4
and RMA target cells (Figure 3.6). I also observed a reduction of cytotoxic activity against
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C4.4.25 and RMA/S, MHC class I-deficient variants of EL4 and RMA cells, respectively.
Furthermore, using freshly isolated Vav-1-/- NK cells, I found a marked reduction in
cytotoxicity against YAC1 cells. My data demonstrate that Vav-1 is essential for NK
spontaneous cytotoxicity and that Vav-1 may act in an activation process that is independent
of MHC class I. In contrast to freshly purified NK cells, Vav-1-/- LAK cells exhibit normal
cytotoxic activities against YAC1 cells. One possible explanation for this altered degree of
tumorcidal activity could be the upregulation of death receptors such as FasL and TRAIL in
LAK cells (Kayagaki et al., 1999). A change in the expression pattern of receptors could
overcome the requirement for Vav-1 leading to efficient lysis of YAC1 cells. Alternatively,
subsets of Vav-1 dependent activating receptors involved in the lysis of YAC1 cells down-
regulated in LAK cells. Together, my data are consistent with another study on Vav-1-/- LAK
cells which also showed abated spontaneous cytotoxicity against YAC-1, RMA/s and b 2m-/-
Con A blasts. Furthermore, NK cells activated by injection of poly(I:C) in vivo also displayed
reduced spontaneous cytotoxicity aginst YAC-1 and IC-21 (Colucci et al., 2001).
Spontaneous cytotoxicity of NK cells can be enhanced by ligation of CD16 (or Fcg RIII). This
process, known as antibody directed cell mediated cytotoxicity (ADCC), remained intact in
the absence of Vav-1 (Figure 3.4 A). In fact CD16-mediated ERK, JNK, and p38 activation in
Vav-1-/- LAK were also normal (Figure 3.4 B). These findings are inconsistent with the
previous notion that Vav-1 is a downstream effector of CD16 and a mediator of ADCC in
human NK cells (Billadeau et al., 1998; Galandrini et al., 1999). One explanation could be
that other Vav proteins such as Vav-2 and Vav-3 can compensate for Vav-1 function in Vav-
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1-/- NK cells. The expression of Vav-2 in NK cells and its reported participation in human NK
ADCC further illustrated Vav-2 as potential candidate capable of taking over Vav-1 function
(Billadeau et al., 2000). This possibility is unlikely in the murine model since Vav-2-/- NK cells
mediate normal ADCC (Figure 3.8). In fact, ADCC and CD16-induced MAPK activation are
also normal in Vav-1-/-Vav-2-/- NK cells (Figure 3.8 A and B). These data indicate that neither
Vav-1 nor Vav-2 act downstream of CD16. Alternatively, Vav-3 could overtake the functions
Vav-1 and Vav-2 in their absence. However, it is not known whether Vav-3 is expressed in
NK cells. Interestingly, another study demonstrated reduced ADCC activity mediated by Vav-
1-/- NK effectors (Colucci et al., 2001). However, the target cells used by Colucci and co-
worker were EL4 cells and the mice were of different genetic background. The combination
of these factors could explain some of the discrepancies.
Vav-1 catalyse the activation of Rho GTPases, such as Rac1, Cdc42, and RhoA (Bustelo,
2000). Given that both Vav-1 and Rac1 are implicated in NK cytotoxicity (Billadeau et al.,
1998; Galandrini et al., 1999), it is likely that Vav-1-/- NK cell defect results from a failure to
activate Rac1. Interestingly, Rac2, a member of the Rac subfamily is expressed strictly in
hematopoietic lineage (Reibel et al., 1991). Furthermore, Rac2-/- and Vav-1-/- mice share
many striking similarities. T cells from both mice show reduced TCR-mediated proliferation,
ERK activation, and Ca2+ mobilization (Yu et al., 2001). TCR-induced actin polymerization
and TCR capping are also reduced in both mutant T cells (Yu et al., 2001). Although the
functions of Rac family members have not been examined, it is likely that Rac1 and Rac2 are
downstream targets of Vav-1 in NK cells.
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Vav-1 functions not only as a GEF for Rho GTPases, but can also serve as an adaptor in
recruiting many molecules to the signaling complexes downstream of activated receptors.
Interestingly, some of these Vav-1 binding proteins can also mediate NK cytotoxicity. For
example, Syk has been shown to bind to Vav-1 (Deckert et al., 1996), and it is known to be
recruited to DAP12 upon NK activation (Lanier and Bakker, 2000). However, in Syk-/- mice,
NK natural cytotoxicity is normal, while CD16-mediated ADCC and IFNg  production are
reduced (Colucci et al., 1999). This is different from Vav-1-/- NK cell which show a decrease
in spontaneous cytotoxicity but normal ADCC and CD16-mediated IFNg  production (Figure
2.4, 2.5, 2.6 and data not shown). These results suggest that Vav-1 and Syk are involved in
distinct signaling pathways in NK cells.
ZAP-70, another Syk family kinase, can also bind to Vav-1 (Katzav et al., 1994). ZAP-70-/- NK
cells exhibit normal cytotoxicity (Iwabuchi et al., 2001), suggesting that either ZAP-70 is not
essential for NK cell cytotoxicity, or that the Syk can compensate for the loss of ZAP-70
function in ZAP-70-/- NK cells. However, a recent report showed that Syk-/-ZAP-70-/- NK cells
are still capable of killing a panel of tumors cells (Colucci et al., 2002), thus raising a possible
involvement of an unidentified kinase in compensating the loss of both Syk and ZAP-70.
SLP-76 is another adaptor molecule that can associate with Vav-1 in T cells (Onodera et al.,
1996; Wu et al., 1996). However, NK cells derived from SLP-76-/- mice show normal cytokine
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secretion and cytotoxicity, thus ruling out a functional coupling of Vav-1 and SLP-76 in NK
cells (Peterson et al., 1999).
Biochemical evidence showed that the Src family kinase Lck can phosphorylate Y174 in Vav-
1 (Crespo et al., 1997; Han et al., 1997), thus relieving autoinhibition by exposing the DH
domain, leading to an enhanced GEF activity towards Rho GTPases (Aghazadeh et al.,
2000). Such observations would predict Src family kinases lying upstream of Vav-1.
However, in Lck-/-, Fyn-/- and Lck-/-Fyn-/- mice, NK cytotoxicity is normal (van Oers et al.,
1996), suggesting these kinases are not involved in regulating Vav-1 activation in NK cells. It
is known that another Src family kinase, Hck, is expressed in human NK cells (Biondi et al.,
1991), raising the possibility that it is involved in Vav-1 phosphorylation and activation.
One of the earliest events of NK cell activation is the release of perforin and serine proteases
such as granzyme B (Henkart et al., 1984; Young et al., 1986). This event is dependent on
the activation of ERK (Trotta et al., 1998; Wei et al., 1998). Interestingly, Vav-1-/- T cells are
unable to activate ERK in response to TCR stimulation (my unpublished observation)
(Costello et al., 1999). It is therefore likely that a reduced cytotoxic activity in Vav-1-/- NK cells
is due the loss of Vav-1 mediated ERK activation, leading to the reduction of cytotoxic
granule release. Consistent with this model, Colucci et al (2001) showed a marked reduction
of granyzme release in Vav-1-/- NK cells upon stimulation with YAC-1 cells (Colucci et al.,
2001). I have shown that CD16 mediated ERK activation and cytotoxicity are normal in the
absence of Vav-1 (Figure 3.4), indicating that in NK cells, ERK could be activated by both
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Vav-1 dependent and independent pathways. CD16 can mediate ERK activation
independent of Vav-1, leading to granzyme release and tumor cell lysis.
Since the presence of Vav-1 is crucial in NK spontaneous cytotoxicity, it might mediate
signals of stimulatory NK receptor(s). Although several receptors have been implicated in NK
natural cytotoxicity, most of these studies were done with human cell lines and it is not
known whether all these receptors are conserved in the murine model (Moretta et al., 2001).
Vav-1 was shown to be a downstream target of Ig family receptors such as TCR, BCR, CD19
and Fce RI. Homologous to these are the human NK receptors NKp44, NKp46 and NKp30
belonging to the Ig superfamily. They also associate with co-receptors bearing ITAM motifs,
and were shown to be key stimulatory receptors for NK cell activation (Moretta et al., 2001).
It is therefore likely that Vav-1 can act downstream of NKp44, NKp46 and/or NKp30.  To
date, only the NKp46 mouse analogue has been identified but the intracellular signals
mediated by NKp46 remain unknown (Biassoni et al., 1999).
Upon engagement of NK cells and target cells, membrane lipid rafts become polarized to the
site of cell-cell contact, a process partially dependent on the activation of both Src and Syk
family kinases  (Lou et al., 2000). The polarization of lipid rafts is sensitive to signals
mediated by inhibitory receptors ligation and SHP-1 activation (Fassett et al., 2001; Lou et
al., 2000). Vav-1 is required for TCR mediated lipid raft clustering since in Vav-1-/- T cells raft
aggregation is severely reduced in response to CD3-CD28 stimulation (Krawczyk et al.,
2000). Furthermore, when mutant T cells are stimulated with peptide-loaded antigen
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presenting cells (APCs), lipid rafts did not translocate to the immunological synapse (Villalba
et al., 2001). Similarly, introducing dominant negative mutant of Vav-1 to Jurkat cells lead to
a failure of raft polarization at the site of cell-cell conjugation (Villalba et al., 2001). These
observations suggest that Vav-1 also mediates raft aggregation at the NK cell-target cell
synapse. A possible scenario could involve ligation of stimulatory NK cell receptors leading to
Vav-1 and Rho GTPases activation which results in polarization of rafts at the site of cell-cell
contact. This lead to the displacement of NK inhibitory receptors from the signaling
complexes at the lipid raft scaffolds (Fassett et al., 2001; Lou et al., 2000). The removal of
inhibitory receptors allows sustained stimulatory signaling in NK cells, leading to the
activation of ERK, which mediates cytotoxic granule release resulting in the lysis of target
cells (Henkart et al., 1984; Young et al., 1986) (Figure 4.1). Future experiments are
necessary to define a more precise mechanism of raft polarization and how Vav-1 might take
part in this process.
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 4.2 Lsc is a negative regulator of NK cell cytotoxicity
Experiments on Vav-1-/- NK cells highlight the importance of GEFs in NK cell activation.
Since many Rho GTPase-mediated processes are normal in Vav-1 deficient NK cells, it is
likely that other GEFs are also involved in NK cell activation. Lsc is another Rho GEF that is
expressed specifically in the hematopoietic system including LAK cells and freshly purified
CD3-DX5+ NK cells (Figure 3.11A (Girkontaite et al., 2001)). Data presented in this
manuscript show that Lsc is not required for NK cell development (Figure 3.11). However,
NK cells derived from Lsc mutant mice show enhanced cytotoxicity responses against three
different tumor targets (Figure 3.12 and 3.13). This may be due to a loss of inhibitory signals
in mutant cells. Lsc acts downstream Ga 12 and Ga 13 coupled receptors (Kozasa et al.,
1998) (Mao et al., 1998b) (Majumdar et al., 1999) (Hart et al., 1998). Although Ga 12 is
express in LAK cells, no function has been ascribed (Al-Aoukaty et al., 1997). There is also
no evidence that G-protein coupled receptors are involved in NK cell cytotoxicity. Indeed, all
major NK cell stimulatory and inhibitory receptors belong to either the lectin-like family or Ig
superfamily (Moretta et al., 2001).
The GTPase Rho is known to promote NK cell cytotoxicity (Lou et al., 2001). As Lsc is a
known activator of RhoA (Hart et al., 1998; Hart et al., 1996), one would have predicted that
NK cell cytotoxic responses are abated in the absence of Lsc. This is contrast to the
enhanced cytotoxic activity of Lsc-/- NK cells. Since expression of cell surface markers on
both wild type and mutant cells are nearly identical (Figure 3.11), they suggest that Lsc
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mutant NK cells are not pre-activated in vivo, but they elicit aberrant activation signals upon
engagement with tumor targets. It is possible to envisage that negative regulation of
G a 12/Ga 13 is lost in the absence of the RGS domain of Lsc, leading to the hyper-activation
of these G-proteins. This in turn could result in a constitutive activation of downstream
signaling cascades, and ultimately hyper-reactive NK cells.
Lsc traffics signals derived from Ga 12 and Ga 13 coupled receptors (Kozasa et al., 1998).
Interestingly, a lymphoid-expressed G-protein coupled receptor (GPCR) G2A has been
identified as functionally associates with Ga 13 (Kabarowski et al., 2000) and regulates
lymphocyte homeostasis (Le et al., 2001). This raises the possibility that Lsc acts
downstream of G2A. Genetic evidences seem to support this notion, since G2A-/- and Lsc-/-
mice have similar phenotypes such as an enlargement of lymph nodes and spleen as the
mice age, and hyperactive T cells ((Le et al., 2001) and Girkontaite, I., unpublished data).
The identification of receptors upstream of Lsc warrants further investigation.
.
During the course of this study, I observed that co-incubation of Lsc-/- T cell depleted
splenocytes together with YAC-1 cells led to an increase in TNFa secretion by mutant cells
(Figure 3.14). This enhanced production of TNFa  was not responsible for the increase in
cytotoxicity as neutraling anti-TNFa  antibodies did not dampen tumorcidal activities of both
wild type and Lsc mutant cells (Figure 3.15). Preliminary evidence indicated that the
population secreting TNFa  is DX5-CD3-B220-Mac1+ (data not shown), suggesting these cells
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are not T cells, B cells and NK cells. The expression of Mac1 on these cells suggests that
they are monocytes, macrophages, or dendritic cells. Recently, it was observed that dendritic
cells (DCs) can produce TNFa  in the presence of activated NK cells (Ferlazzo et al., 2002;
Gerosa et al., 2002; Piccioli et al., 2002). As Lsc-/- NK cells were hyperactive, they might
trigger neighboring DCs to produce TNFa . To determine whether secretion of TNFa  is
dependent on the presence of activated NK cells, future experiments will involve depleting
DX5+ NK cells from splenocytes and examine whether the burst of TNFa  is concomitantly
ablated.
In summary, the data presented in this thesis provided the first genetic evidence that Rho
GEFs are critical regulators of NK cell activation and function. Importantly, Rho GEFs
participate in both stimulatory and inhibitory functions as exemplified by Vav-1 and Lsc
respectively. These data also show for the first time a RGS domain containing GEF in down-
modulating NK cytotoxic responses. Significantly, these observations highlight the possibility
that in addition to known cell surface receptors such as the lectin and Ig family members,
GPCRs are also involved in regulating NK activation.
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